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Acute and chronic respiratory diseases continue to be a leading cause of death in the United 
States.1 Mechanical ventilation has been used to treat these patients, however this can further 
damage the lungs.2 Patients with acute hypercapnic respiratory failure have benefited from 
extracorporeal CO2 removal (ECCO2R) in conjunction with non-invasive or lung-protective 
ventilation. For patients with end-stage lung disease extracorporeal membrane oxygenation has 
been used as a bridge-to-transplant. Active rehabilitation while on these devices has shown 
improved outcomes, however is limited by current, cumbersome systems. 
We are developing the Modular Extracorporeal Lung Assist System (ModELAS) as a 
compact, wearable, platform artificial lung. The ModELAS may be configured for adult low-flow 
ECCO2R, and pediatric or adult full respiratory support through an exchange of the fiber bundle. 
The platform nature of this technology allows the pediatric application to leverage the larger adult 
markets and is likely the most feasible pathway to market for a pediatric device.  
This dissertation investigates the ECCO2R and pediatric applications of the ModELAS. A 
mathematical model was used to define the ECCO2R bundle geometry, and benchtop performance 
was evaluated followed by in vivo testing. The minimum CO2 removal target of 70 mL/min CO2 
removal was met at a blood flow rate of ~250 mL/min. Benchtop studies determined a significant 
relationship between hematocrit and artificial lung CO2 removal. In vivo plasma-free hemoglobin 
remained below 25 mg/dL and no thrombus formed within the device under normal operation. 
 
v 
The P-ModELAS was evaluated in 6-hr and 7-day animal studies to validate benchtop 
performance and optimize cannulation and post-surgical recovery strategies, respectively. The P-
ModELAS fully saturated blood while generating less than 20 mg/dL plasma-free hemoglobin. 
From these studies, an RA to PA cannulation via a right thoracotomy and maintaining a post-
surgical 25 IU/kg/hr heparin infusion until the chest tube output stabilizes will be used in upcoming 
30-day studies.  
In vitro methods were developed to evaluate the effect that the ModELAS impeller design 
modifications have on thrombus formation at the bottom pivot-bearing. Smoother, zirconium 
pivots did not appear to decrease thrombus formation compared to ceramic pivots. Washout holes 
did not further improve thrombus formation.  
vi 
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1.0 Introduction 
1.1 Adult Respiratory Failure 
Chronic lung disease in adults, including chronic obstructive pulmonary disease (COPD), 
continue to be the 3rd leading cause of death in the US and 5th worldwide.1,3 Annually, COPD 
results in over 800,000 hospitalizations and is projected to continue to increase due to an aging 
population and increased tobacco use in developing countries.4,5 COPD is characterized by a 
chronic cough, dyspnea, and diminished lung function.6 It encompasses multiple respiratory 
conditions including chronic bronchitis (mucus over secretion) and emphysema (alveoli 
destruction).5 The primary cause of COPD is smoking, however environmental/occupational 
pollutants and genetic factors may also increase one’s risk of developing COPD.6 COPD 
symptoms may be managed pharmacologically to improve quality of life and reduce the frequency 
and severity of acute exacerbations, however the lung damage associated with COPD is 
irreversible.6 
Acute exacerbations of COPD (ae-COPD) are defined by worsening dyspnea and 
hypercapnia, hypoxemia and an increased amount of mucus.7 Acute exacerbations are commonly 
due to viral or bacterial infections, but are also attributable to environmental factors and smoking. 
COPD patients typically experience 2 – 3 acute exacerbations per year, and account for 
approximately 63% of COPD hospitalizations.4,5 One study reported a 43% one-year mortality rate 
for COPD patients requiring hospitalization for an acute exacerbation.8 The current standard of 
care for moderate to severe ae-COPD is mechanical ventilation to correct blood gas tensions while 
the cause of the exacerbation is addressed.  
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Acute respiratory distress syndrome (ARDS) is an acute form of respiratory disease which 
accounts for 200,000 hospitalizations in the US per year and is associated with a 30 – 50% 
mortality rate.9 ARDS develops secondary to a direct (pneumonia, aspiration, air emboli) or 
indirect (sepsis, drug overdose, trauma with transfusions) lung injury.10,11 The Berlin Definition is 
commonly used to identify ARDS and requires noncardiogenic bilateral opacities on radiographic 
chest imaging, symptomatic within 7 days of injury and a minimum positive end-expiratory 
pressure of 5 cm of water (measure of the degree of hypoxemia).12 The intensity and invasiveness 
of ARDS treatment is dependent upon the severity of the lung injury as indicated by the PaO2/FiO2 
ratio and ranges from non-invasive ventilation to extracorporeal membrane oxygenation.13  
1.1.1 Treatments 
Carbon dioxide removal is the primary challenge in patients with ae-COPD and moderate 
ARDS. These patients maintain adequate lung function to oxygenate blood via minimally invasive, 
or non-invasive methods, however they are unable to utilize the lung volume required for CO2 
removal.  
1.1.1.1 Mechanical Ventilation 
Invasive mechanical ventilation (IMV) has conventionally been used to provide the 
necessary respiratory support for moderate ARDS and ae-COPD patients. The high tidal volumes 
(10 – 15 mL/kg) required to effectively ventilate these patients can result in ventilator-induced 
lung injury (VILI) thereby exacerbating the initial lung injury. VILI encompasses both barotrauma 
and volutrauma caused by the over distension of the lungs as well as potential biotrauma resulting 
from the release of bacteria into the circulation.2 Prolonged failure to wean patients form IMV 
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places patients at an increased risk for developing respiratory muscle fatigue14 and can lead to 
extended IMV use15 which is associated with increased mortality.16 
Lung protective ventilation (LPV) and ultra-LPV (<6 mL/kg or 3mL/kg, respectively)17,18 
utilize lower tidal volumes to prevent VILI. These strategies are able to adequately oxygenate the 
blood in moderate ARDS and ae-COPD patients, however 15 – 26% of patients will fail LPV 
strategies due to CO2 retention.
19,20 The resulting hypercapnia, acidosis, and dyspnea often 
necessitates placing the patient on IMV.21,22 Mortality rates are higher for patients who fail LPV 
and are subsequently placed on IMV compared to patients who were initially supported with 
IMV.23 
1.1.1.2 Extracorporeal CO2 Removal 
Extracorporeal CO2 removal (ECCO2R) devices have been used in conjunction with LPV 
to reduce the hypercapnia by providing partial CO2 removal independent of the lungs. The partial 
CO2 removal has also allowed some ae-COPD patients to be extubated while on ECCO2R. 
Although initially plagued by high complication rates, ECCO2R has gained traction as 
advancements in fiber technology, biocompatible coatings, and simplified circuits have made 
extracorporeal support safer.  
ECCO2R utilizes analogous gas exchange principles as extracorporeal membrane 
oxygenation (ECMO). Targeting CO2 removal rather than oxygenation, however allows ECCO2R 
devices to be operated at much lower extracorporeal blood flow rates than ECMO devices while 
still removing clinically relevant amounts of CO2 (60 – 100 mL/min at normocapnia). This is due 
to the high solubility of CO2 within plasma and the nearly linear slope of the CO2 dissociation 
curve within the physiologically relevant range.24,25 The high solubility of CO2 is primarily due to 
the majority of CO2 being carried as bicarbonate (>95%).
26 Bicarbonate is rapidly converted to 
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dissolved CO2 as it is eliminated thereby an unsaturated, linear dissociation curve within the 
physiologic range is maintained. The resting, normocapnic CO2 production in an adult (~200 
mL/min) is equivalent to the CO2 carried in ~400 mL of blood.
27 Thus, even when resistances to 
gas transfer within an artificial lung are taken into account28, clinically relevant CO2 removal can 
be achieved at blood flow rates below 1 L/min. Comparatively, typical blood flow rates for adult 
ECMO are 4 – 8 L/min (50 – 100 mL/kg/min).29 The lower extracorporeal blood flow rates 
associated with ECCO2R allow smaller cannulas to be used, and is generally considered less 
invasive than ECMO. 
1.1.1.2.1 Arteriovenous ECCO2R (AV-ECCO2R) 
Low resistance, polymethylpentene (PMP) hollow fiber membrane bundles (5 
mmHg/L/min) permit the use of the arterio-venous pressure gradient to generate flow through the 
hollow fiber membrane (HFM) lung. This eliminates the need for a pump and consequently 
reduces the trauma to the blood. The iLA Membrane Venilator (Novalung, Xenios AG, Heilbronn, 
Germany) is the most widely used AV-ECCO2R device and was first introduced in 2002.
30 The 
iLA utilizes a 1.3 m2 heparin coated PMP bundle and has a blood flow specification of 0.5 – 4.5 
L/min.31 Complications associated with arterial cannulation and specific patient selection criteria 
have limited the clinical appeal of AV-ECCO2R. The most serious complication is limb ischemia 
due to the large bore arterial cannula. Zimmerman, et al. report lower limb ischemia in 6% of 
patients even with the use of ≤17 Fr arterial cannula, a two physician insertion process and 
ultrasound assessment of the vessel.32 AV-ECCO2R is also contraindicated in patients with heart 
failure or peripheral vascular disease due to its reliance on the cardiac function to drive 
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extracorporeal blood flow. The fraction of the cardiac output flowing through the membrane lung 
bypasses the peripheral vascular, thereby essentially reducing the patient’s cardiac output.30 
1.1.1.2.2 Veno-venous ECCO2R (VV-ECCO2R) 
Early forms of VV-ECCO2R were first explored in the 1970s, however these circuits 
essentially operated ECMO devices at lower blood flow rates.33 These early devices utilized large 
surface area (1.6 – 3.5 m2) silicone membranes, required two venous access cannulas and operated 
at blood flows between 2 and 4 L/min.27,34 A 1994 randomized clinical trial, however did not show 
improved survival for patients treated with low frequency positive pressure ventilation in 
conjunction with ECCO2R.
34 
Recently, clinical interest has returned to VV-ECCO2R. Modern VV devices utilize PMP 
HFM bundles, operate at blood flow rates below 1 L/min and vascular access can be gained via a 
percutaneously placed dual lumen catheter. The complexity of these systems is increased 
compared to AV-ECCO2R due to the need for a blood pump. Pump-driven extracorporeal blood 
flow removes the reliance on the heart to generate the pressure gradient and obviate the need to 
arterial cannulation. Multiple companies are actively pursuing artificial lungs specifically designed 
for VV-ECCO2R. These systems remove 20 – 40 % of the basal metabolic CO2 production and 
operate at blood flows ranging from 250 mL/min to 4.5 L/min.35–37  
The Hemolung RAS (ALung Technologies, Pittsburgh, PA) utilizes an integrated spinning 
core to enhance gas exchange efficiency within the 0.59 m2 annular HFM bundle.38,39 This allows 
the Hemolung to remove 30 – 50% of the metabolic CO2 production at blood flow rates below 500 
mL/min. Multiple small case reports have utilized the  Hemolung in conjunction with NIV to avoid 
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intubation, allow extubation or aid in weaning patients from MV in ae-COPD patients.40–44 In 
ARDS patients the Hemolung has been used in addition to lung-protective ventilation strategies to 
manage hypercapnia.45–47 In the SUPERNOVA Trial (ClinicalTrials.gov Identifier: 
NCT02282657) the Hemolung facilitated MV tidal volumes below 4 mL/kg in ARDS patients.48 
The iLA Activve (Xenios, AG, Heilbronn, Germany) product line provides low-, mid- and 
high-flow to provide ECCO2R to ECMO support through three different membrane lung options.
31 
In the ECLAIR clinical trial, the mid-flow iLA Activve device (1.3 m2) prevented intubation in 
56% of the acute hypercanic respiratory failure patients compared patients initially started on NIV 
therapy. Major bleeding, however occurred in 9 of the 25 ECCO2R patients compared to 2 patients 
in the control MV group.49 Clinical and benchtop evaluations of the low-flow, partial CO2 removal 
iLA Activve device, the MiniLing Petite (0.32 m2 and blood flows up to 0.8 L/min) have not been 
published. 
The low blood flow rates required for ECCO2R has resulted in several systems leveraging 
the capabilities of renal replacement therapy platforms, already widely used in intensive care units, 
to drive blood flow. The 0.32 m2 PrismaLung (Gambro-Baxter, Meyzieu, France) is integrated into 
the Gambro Prismaflex system.50 In a feasibility and safety study of 20 mild to moderate ARDS 
patients an average CO2 removal of 51 mL/min was achieved at a blood flow of ~420 mL/min. 
Although the 28-day mortality was 15%, in 50% of the cases the membrane lung had clotted within 
20 hours.51 The Abylcap (Bellco, Mirandola, Italy) couples the Lilliput 2 oxygenator (0.67 m2, 
LivaNova) and the Bellco renal replacement systems to provide CO2 removal at blood flow rates 
below 500 mL/min.52 A 4 patient study utilizing the Abylcap in ARDS patients showed up to 98 
mL/min CO2 removal at a blood flow rate of 400 mL/min.
53 Neither device however has gained 
significant clinical use. 
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Evidence supporting the use of ECCO2R in ARDS and ae-COPD patients continues to 
grow, however is primarily limited to case reports, and prospective and retrospective studies. This 
has led some to caution referring to ECCO2R as less invasive and safer than ECMO,
49,54 and 
limited the commercial use of ECCO2R to outside of the United States. Pivotal clinical trials 
currently underway are required to gauge the safety and efficacy of ECCO2R over traditional 
therapies. The VENT-AVOID trial in the US (ClinicalTrials.gov Identifier: NCT03255057) is 
evaluating the safety and efficacy of the Hemolung RAS plus standard of care MV compared to 
standard of care MV alone in COPD patients. The REST trial in the UK (ClinicalTrials.gov 
Identifier: NCT02654327) is comparing outcomes of ARDS patients treated with VV-ECCO2R 
plus low tidal volume MV to those treated with standard of care MV. 
1.2 Pediatric Respiratory Failure 
Chronic and acute respiratory failure continue to be prominent sources of pediatric 
morbidity and mortality. Acute respiratory infections in pediatric patients account for 17% of 
reported pediatric deaths.55 Cystic fibrosis (CF) and pulmonary hypertension (PH) are the primary 
chronic lung diseases which affect children. CF affects approximately 70,000 people worldwide 
and has a mean survival of 37.4 years.6,56 The genetic mutation responsible for CF results in the 
thickening of the lung mucus which causes clearing the mucus from the airways to be challenging. 
The result is difficulty breathing and an elevated risk for lung infections. CF is not curable and 
treatment focuses on preventing lung infections, and techniques and medicines to clear mucus from 
the lungs.6 Lung transplantation is currently used as a life-extending treatment for those patients 
with advanced CF.57 
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PH in children is primarily idiopathic pulmonary artery hypertension (PAH), inherited 
PAH or PAH associated with congenital heart disease, however it can also be secondary to 
developmental lung diseases.58 PH is defined as a mean pulmonary artery pressure ≥25 mmHg 
after 3 months of age and is a result of thickening of the muscle within the walls of the pulmonary 
blood vessels.59 The increased pulmonary resistance requires additional work by the right heart 
which leads to right heart failure. Although there is no cure for PH, pharmacological agents are 
used to treat symptoms and slow disease progression. Pulmonary vasodilators have increased the 
5-year survival from PAH diagnosis to 74%.60 Lung and heart-lung transplantation are options for 
end-stage PH, however outcomes and survival are poor. Median survival for transplanted IPAH 
patients is 5.8 years, with a 61% 5-year survival rate.61 
1.2.1 Treatments  
Early stages of CF and PAF can be managed non-invasively via non-invasive ventilation 
and pharmacological methods. As these diseases progress patients ultimately require lung 
transplantation. CF and PH are the most common indicators for lung transplantation in pediatric 
patients62 with patients typically waiting 1 – 6 months for donor lungs to become available.63 
Mechanical ventilation and ECMO are used to bridge these lung failure patients to transplant.  
Invasive mechanical ventilation in pediatric respiratory failure patients, however has 
similar drawbacks to its use in adults. The potential for VILI is increased in end stage pediatric 
lung failure due to the long lung transplant waitlist times. A single center study evaluating post-
transplant outcomes of pediatric CF patients demonstrated significantly more graft failures (55.6% 
vs 11%) and longer mean post-transplant hospital stays in patients who had been ventilated pre-
transplant.64 Lung protective ventilation techniques used in adult ae-COPD and ARDS patients are 
9 
not appropriate for these pediatric patients due to their need for both oxygenation and CO2 removal 
support. 
ECMO provides full respiratory support (oxygenation and CO2 removal) independent of 
the lungs and can be used as an alternative therapy to IMV. Significant progress has been made in 
adult ECMO technology, however the pediatric population has not seen similar advances. This is 
primarily due to the small pediatric patient population, and subsequent small financial returns, and 
the wide range of patient sizes (< 2kg in neonates to >70 kg in older children).65 Clinicians are 
able to use adult devices off-label in large children, however off-label use is not feasible in smaller 
children and neonates. 
Devices available for pediatric ECMO are limited and commonly require piecing together 
pumps and oxygenators from multiple manufacturers. The Quadrox iD neonatal and pediatric 
oxygenators (Getinge Group, Germany) and the NovaLung iLA (Xenios, Germany) provide 
pediatric specific support with maximum blood flow rates of 1.5, 2.8, or 4.5 L/min, 
respectively.31,66 In pulmonary hypertension patients, blood flow through low resistance 
oxygenators, such as the Quadrox Neonatal and Novalung, is able to be driven via the pressure 
gradient between the pulmonary artery and typically either the pulmonary vein or left atrium, 
essentially bypassing the lungs.67,68 In a VV configuration these oxygenators would need to be 
paired with a pump, such as the Pedimag.  
The literature has also suggested that devices marketed for ECCO2R could also be operated 
as pediatric ECMO devices.65 The blood flow rates and HFM bundle surface area of ECCO2R 
devices are well suited for pediatric ECMO. Jeffries, et al. demonstrated in a preclinical animal 
study that the Hemolung was able to provide the required oxygen transfer for 3 – 10 kg children.69 
This, however, is the only study evaluating the application of an ECCO2R device for pediatric 
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ECMO. A significant drawback to using either an adult ECMO or ECCO2R device off-label for 
pediatric ECMO is that the devices have not been optimized for pediatric needs (i.e. larger than 
necessary HFM surface area). 
ECMO, and MV, are typically deemed contraindications for lung transplant by some 
centers due to poor post-transplant outcomes. In one retrospective study survival to discharge was 
66% for patients weaned from ECMO prior to transplant and 22% for those patients unable to be 
weaned.70 Neither current ECMO circuits nor MV is well-suited for long-term pediatric respiratory 
support due to the required immobilization and sedation of the patient, and resultant muscle 
deconditioning. Post-transplant outcomes, however, have been improved in ECMO patients who 
participated in active rehabilitation, including ambulation, pre-transplant.71 Pre-transplant active 
rehabilitation of ECMO patients has been used to counter muscle deconditioning.72–75 A small 
study from Duke Children’s Hospital, demonstrated patients involved in pre-transplant 
rehabilitation had significantly fewer post-transplant days on MV, and fewer post-transplant days 
in the ICU and hospital compared to patients not participating in pre-transplant rehabilitation.75 
The majority of reported “awake ECMO” however has been in adult and adolescent patients rather 
than younger children.71,76–79 This is partly due to limited availability of appropriately sized dual 
lumen catheters for children and, hence reliance on multisite VV-cannulation which increases 
circuit complexity.80 
Current research efforts are focused on devices specific to pediatric gas transfer 
requirements and that also allow safe, and simplified patients ambulation. The University of 
Michigan group is pursuing a pediatric pump-less, low resistance oxygenator. The Pediatric 
MLung (0.13 m2) uses concentric gating to create secondary flow and increase gas transfer. Animal 
studies have demonstrated an oxygenation rate of 45 mL/min and pressure drop of 25 mmHg at 
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the rated flow (1 L/min).81 The University of Maryland group and Breethe Inc. are developing the 
Pediatric Pump Lung (PediPL) which combines a centrifugal pump and HFM bundle (0.3 m2) into 
a single, wearable unit. The PediPL has demonstrated positive performance in 30-day sheep 
studies.82 
1.3 The Modular Extracorporeal Lung Assist System (ModELAS) 
This thesis presents work contributing to the development of the Modular Extracorporeal 
Lung Assist System (ModELAS). The ModeLAS is being designed as a platform artificial lung 
capable of meeting the needs of three respiratory assist applications. Full adult or pediatric 
respiratory support (oxygenation and CO2 removal) and adult low-flow CO2 removal may be 
achieved by the ModELAS. All three applications utilize the same centrifugal pump and a simple 
exchange of the HFM bundle permits the ModELAS to be configured for either pediatric or adult 
use. 
The ModELAS was developed from the Paracorporeal Ambulatory Assist Lung (PAAL)83 
and the Pittsburgh-Pediatric Ambulatory Lung (P-PAL)84. All three devices utilize the same 
centrifugal pump, and the pediatric and adult versions of the ModELAS utilize the identical HFM 
bundles as the P-PAL and PAAL, respectively. The blood flow channel leading from the pumping 
compartment to the HFM bundle in the ModELAS is identical to that in the PAAL. Due to the 
commonalities in the internal geometries and the design evolution from the PAAL and P-PAL to 
the ModELAS some work presented in this thesis was conducted in the PAAL and P-PAL. 
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1.3.1 Benefits of a Platform Technology 
Commercialization and innovation of pediatric specific medical devices is often hindered 
by the small pediatric patient population. The cost of developing and conducting clinical trials on 
pediatric specific devices typically exceeds their future profitability, and thus these devices attain 
little interest from industry.85 To combat this issue Pediatric Medical Device Safety Improvement 
Act (PMDSIA) established in 2007 the Pediatric Device Consortia to fund pediatric device 
development and provided fiscal incentives for devices approved under the Humanitarian Device 
Exemption.86 Since its enactment the PMDSIA has increased the percentage of PMA and HDE 
approved devices indicated for pediatric patients per year from 6.9% in 2008 to 18.3% in 2016.87 
The majority of these devices in 2016, however were approved for patients 18 years and older, or 
for pediatric and adult use. Thus, despite the PMDSIA incentives, there does not appear to be an 
industry shift towards developing pediatric medical devices unless there is also an adult 
application. 
The ModELAS, being a platform technology, follows this trend by having both a pediatric 
as well as adult applications. The adult ECCO2R ModELAS patient population is nearly two orders 
of magnitude larger than the pediatric population (Table 1). By targeting a combined adult and 

















O2 supply and 
CO2 removal 
1 – 2.5 ~500 
    
Adult Support 
O2 supply and 
CO2 removal 
1 – 5 ~2,000 
    
ECCO2R CO2 removal < 1 ~200,000 
 
1.3.2 Objective for the ModELAS 
This dissertation focuses on the development of the ECCO2R and pediatric respiratory 
support applications of the ModELAS. Performance targets were established based upon devices 
which are clinically available as well as those under development. The design targets for the 
ECCO2R ModELAS configuration are removal of 35 – 50% of the metabolic CO2 produced at a 
blood flow rate less than 700 mL/min (approximately 70 – 100 mL CO2/min at normocapnia), 
compatibility with the Hemolung 15.5 Fr dual lumen catheter, non-clinically significant hemolysis, 
and capable of providing 7 days of continuous support. The design targets for the pediatric 
ModELAS configuration are 30 – 105 mL/min oxygenation at a blood flow rate of 1.0 – 2.5 L/min, 
compatibility with a right atrium to pulmonary artery cannulation (including a 50 mmHg 
pulmonary hypertension assumption), a normalized index of hemolysis below 0.05 g/100L, and 
the capability of providing 1 – 3 months of continuous support.  
This thesis describes the development, in vitro and in vivo characterization of the ECCO2R 
and pediatric applications of the ModELAS. Chapter 2 focuses on the in vitro evaluation of the 
ECCO2R configuration of the device. A mathematical model was developed and used to drive the 
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geometric design of the HFM bundle. The proposed design from Chapter 2 was evaluated in 7-day 
animal studies in Chapter 4. Chapters 5 and 6 focus on the in vivo characterization of the pediatric 
ModELAS in 6-hour and 7-day animal studies. The 6-hour, acute animal studies developed the 
pediatric cannulation strategy and evaluated short-term, in vivo device performance. Chapter 6 
builds upon the acute animal studies and developed the post-operative anticoagulation and 
recovery strategies in a series of 7-day studies. Finally, Chapter 7 aims to develop in vitro methods 
to evaluate the effect impeller washout holes have on the thrombogenicity of the ModELAS. 
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2.0 In Vitro Characterization of the Low-Flow PAAL 
The following chapter presents work peer-reviewed and published in the Intensive Care 
Medicine Experimental Journal. Computation fluid dynamics analysis presented within this 
chapter was completed by Greg Burgreen, PhD. 
2.1 Introduction 
Mechanical ventilation is commonly used to help normalize arterial blood gases in patients 
with acute hypercapnia but can also contribute to ventilator-induced lung injury (VILI). VILI 
results from over-distension of the lung, barotrauma and alveolar damage caused by high volume 
ventilation.2,89 Extracorporeal CO2 removal (ECCO2R) provides a minimally invasive option to 
remove CO2 independently of the lungs and allow lung rest. ECCO2R has been used in patients 
with acute exacerbations of chronic obstructive pulmonary disease (ae-COPD) to avoid invasive 
mechanical ventilation, avoid intubation or assist in extubation and in ventilator weaning.40,90,91 In 
patients with moderate acute respiratory distress syndrome (ARDS), ECCO2R has been used in 
conjunction with lung protective or ultra-protective ventilator settings (tidal volume less than 6 
ml/kg17 or 3 mL/kg18, respectively) to reduce VILI and correct acidosis.18,32 
Contemporary ECCO2R devices use simplified designs, biocompatible coatings and 
polymethylpentene fibers to reduce adverse events.25 Dual lumen catheters permit single site veno-
venous (VV) cannulation and obviate the need for, and risks of, arterio-venous (AV) cannulation. 
A 2016 epidemiological study showed that the trend is toward VV cannulation.92 The recent focus 
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has been on improving the gas exchange efficiency of ECCO2R devices. Active mixing, blood 
acidification, electrodialysis and carbonic anhydrase immobilization to the fiber surface are being 
explored in an effort to reduce fiber surface area and further lower blood flow rates.69,93–95 
ECCO2R utilizes similar principles as extracorporeal membrane oxygenation (ECMO), but 
with the main goal of removing CO2 in patients with otherwise sufficient oxygenation and at a 
fraction of ECMO blood flow rates. Lower blood flow rates are usable in ECCO2R due to the 
linear slope of the CO2 dissociation curve within the physiological pCO2 range. Thus, the amount 
of CO2 available per volume of blood decreases linearly with decreasing pCO2. Comparatively, 
the sigmoidal oxy-hemoglobin dissociation curve plateaus at pO2 values above 100 mmHg thereby 
limiting the amount of O2 that can be transferred to the blood.
25 Clinically used ECCO2R blood 
flow rates vary from 180 to 1700 mL/min96 and are classified as either low-flow (< 1 L/min) or 
mid-flow (1 – 2 L/min) with ECMO considered high flow.  
Proponents of mid-flow ECCO2R contend that higher blood flow rates are required to 
decrease the likelihood of thrombus formation and to attain the required CO2 removal rates. Both 
of these concerns stem from the velocity of the blood through the device. Research has shown that 
regions of a device with low blood velocity are prone to thrombus formations,97 and that increasing 
the velocity of the blood past the fibers increases the gas exchange efficiency.98 There are ways, 
however, to engineer an ECCO2R device with increased blood velocity independent of bulk blood 
flow and permit low-flow ECCO2R. The Hemolung RAS and the Ultra-Low Flow ECCO2R 
Device (ULFED) each use active mixing technology to increase the blood velocity at the fiber 
surface while still removing a clinically significant amount of CO2.
38,69 The Hemolung RAS device 
has been successfully used at blood flow rates below 500 mL/min to correct hypercapnia in 
patients.41,45,46 The Low Flow Pittsburgh Ambulatory Lung (LF-PAL) evaluated in this manuscript 
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operates in the low-flow region and uses a narrow bundle cross sectional area to increase blood 
velocity past the fibers.98  
Here the performance of the LF-PAL as a low-flow ECCO2R device is evaluated through 
bench studies. The LF-PAL utilizes a 0.65 m2 bundle integrated with a centrifugal pump into a 
highly compact device aimed at increasing patient mobility. The CO2 removal performance of the 
LF-PAL was modeled and then measured in vitro at blood flow rates up to 700 mL/min. 
Additionally, the hydrodynamic performance of the LF-PAL and the resistance of the Hemolung 
15.5 Fr catheter were measured and used to determine the anticipated operating conditions. Lastly, 
in vitro hemolysis was evaluated in the 0.65 m2 LF-PAL and compared to two control circuits.  
2.2 Methods 
2.2.1 Device Description 
The LF-PAL incorporates the HFM bundle into a highly compact integrated pump-lung. 
The centrifugal pump drives blood flow from the patient, through the HFM bundle and back to the 
patient via a dual lumen catheter located in the jugular vein. The impeller is magnetically coupled 
to, and driven by, an external motor. The device utilizes a 0.65 m2 cylindrical, stacked-type HFM 
bundle with a diameter of 1.75 in. The bundle is manufactured from polymethypentene fiber sheets 
(OXYPLUS, Membrana, Wuppertal, Germany).98 This prototype device weighs 1850 g and is 
intended to have the option to be worn by the patient. The specific design and manufacturing 
details of the LF-PAL devices have been previously published.83 The device has previously been 
evaluated for high flow adult oxygenation,83 but not for low-flow CO2 removal.  
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2.2.2 CO2 Removal Model 
The CO2 removal model was based on a previously published mass transfer correlation and 














 is the blood flow rate, CCO2 is the total concentration of CO2, z is the axial coordinate, 
R is the bundle radius, k is the mass transfer coefficient, av is the surface area by volume ratio, and 
ΔPCO2 is the CO2 pressure gradient between the sweep gas and blood. The average PCO2 in the 
sweep gas is assumed to be 4 mmHg and is based on a previously calculated average of the inlet 
and outlet sweep gas PCO2.
99 
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where q and t are regression parameters equal to 0.128 and 0.369, respectively. A previously 
developed mass transfer correlation99 relating the Sherwood (Sh), Reynolds (Re), and the Schmidt 
(Sc), numbers was used: 
                            
 
 
                          Sh=0.54Re0.42Sc
1/3
                                                       (2-3) 
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The Sherwood number is defined as Sh=
kCO2df
αCO2Df
 , where kCO2 is the mass transfer coefficient, 
df is fiber diameter, αCO2is the solubility of CO2 in blood, and Df is the facilitated diffusivity. The 
Reynolds number is defined as Re =
ρ v
φ a μ
 ,100 where ρ is the fluid density, v is the superficial fluid 
velocity, φ is the cylindrical particle correction factor, a is the surface area per volume of the fiber 
bundle, and μ is fluid viscosity. The Schmidt number is defined as Sc=
vb
Deff
 where vb is kinematic 
viscosity, and Deff is the effective diffusivity which takes into account chemically bound CO2. The 
importance of including facilitated diffusion in the calculation and details on the development of 
these equations have been previously described.99 An ordinary differential equation solver built 
into MATLAB (MathWorks, Natick, MA) and based on the Runge-Kutta method was used to 
solve the differential equation formed by equations 1-3. 
2.2.3 Pump Performance 
The hydrodynamic performance of the 0.65 m2 LF-PAL was evaluated using an 8.5 g/L 
solution of carboxymethylcelluose sodium salt (CMC) (Sigma Aldrich, St. Louis, MO) as the 
working fluid. The viscosity of the CMC solution at 37 °C was 3.5 cP and verified using a capillary 
viscometer (Cannon Instrument Company, State College, PA). The LF-PAL was connected to a 
reservoir submerged in a 37 °C water bath. The rotation rate of the impeller was varied between 
800 and 2000 RPM. Hoffman clamps placed at the inlet and outlet to the LF-PAL were used to 
vary the flow rate between 0 and 1.4 L/min. Pressure was measured at the inlet and outlet to the 
device using a differential fluid pressure transducer (PX771-025DI; Omega Engineering, Inc., 
Stamford, CT). 
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The anticipated catheter for use with the LF-PAL is the Hemolung 15.5 Fr dual lumen 
catheter. The catheter was inserted into a 1600-mL reservoir bag, and pressure was measured at 
the inflow and outflow ports of the catheter using a differential fluid pressure transducer. Pressure 
within the reservoir was assumed to be spatially uniform so that the resistance of the catheter may 
be calculated as the pressure difference between the inflow and outflow tubing connection ports 
of the catheter. Flow was driven by a Biomedicus BP-80 pump (Medtronic, Minneapolis, MN) and 
ranged between 100 and 900 mL/min. 
2.2.4 In Vitro Gas Exchange 
Gas exchange was performed in bovine blood collected from a local slaughterhouse and 
adhered to the ISO7199 standard.101 The blood was filtered (40 μm Pall Biomedical, Inc., Fajardo, 
PR), heparinized (30 U/mL), and treated with Gentamicin (0.1 mg/mL). Blood was diluted to a 
hemoglobin of 12 ± 1 g/dL with phosphate buffered saline. The test circuit (Figure 1) consisted of 
a LF-PAL device, two 6-L compliant blood reservoirs, and an Affinity oxygenator (Medtronic, 
Minneapolis, MN). The reservoir bags were submerged in a water bath to maintain blood 
temperature at 37 ± 1 °C. The blood was recirculated through a single reservoir while the Affinity 
oxygenator was used to balance the blood gases to venous conditions. Once the blood was 
conditioned, clamps were used to divert blood flow through the LF-PAL and into the empty, 
second reservoir. Blood gas measurements were taken before and after the LF-PAL, and analyzed 
by a Rapidpoint 405 blood gas analyzer (Siemens, Deerfield, IL).  
Blood flow rates ranged from 250 to 700 mL/min and were measured by an ultrasonic flow 
probe (Transonic Systems Inc., Ithaca, NY). Hoffman clamps were used to simulate the resistance 
of the Hemolung 15.5 Fr dual lumen catheter (ALung Technologies, Pittsburgh, PA). The pressure 
21 
across the device was monitored with a differential fluid pressure transducer (PX771-025DI; 
Omega Engineering, Inc., Stamford, CT). The normocapnic condition was tested at an inlet pCO2 
of 45 ± 5 mmHg and sO2 of 65 ± 5%. The gas exchange rate at each flow rate was measured in 
triplicate. 
The oxygen sweep gas flow rate was controlled by a gas flow controller (Fathom 
Technologies, Georgetown, TX) and ranged from 9 to 19.5 L/min. A WMA-4 CO2 analyzer (PP 
Systems, Amesbury, MA) measured the CO2 concentration in the sweep gas (FCO2) exiting the LF-
PAL. Steady state was achieved when the CO2 concentration in the sweep gas changed by less 
than 10 ppm. CO2 removal rate (vCO2) was calculated according to equation 4, and normalized to 
an inlet pCO2 of 45 mmHg (vCO2
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where QSG is sweep gas flow rate, Fco2 is the concentration of CO2 in the sweep gas, and 𝑃𝐶𝑂2
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Figure 1 Schematic of the Single Pass In Vitro CO2 Removal Loop 
 
2.2.5 In Vitro Hemolysis 
Bovine blood was collected and prepared as in the gas exchange experiments. The 
hemolysis test circuit consisted of the LF-PAL and the Hemolung 15.5 Fr dual lumen femoral 
catheter in order to reflect clinical use. The LF-PAL was tested at 500 mL/min. The control circuit 
replaced the LF-PAL with a PediMag pump (Thoratec, Pleasanton, CA) and Minimax PLUS 
Hollow Fiber Oxygenator (Medtronic, Minneapolis, MN) and was run in parallel with the test 
circuit. The control circuit was operated at 1500 mL/min (3750-3800 rpm) to match the CO2 
removal rates of the LF-PAL operated at 500 mL/min.103 Hoffman clamps were used to simulate 
inclusion of a 12 Fr arterial cannula (Medtronic Bio-Medicus Cannula #96820-012) and 14 Fr 
venous cannula (Medtronic Bio-Medicus Cannula #96830-014).104,105 Both circuits contained an 
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800-mL compliant blood reservoir (Medtronic; Minneapolis, MN) submerged in a water bath to 
maintain blood temperature at 37 ± 2 °C.  
Blood samples from each circuit were taken every 30 minutes over a 6-hour period to 
measure plasma free hemoglobin (pfHb), hematocrit and hemoglobin. Details of the sampling and 
pfHb measurement methods, calculation of the normalized index of hemolysis (NIH) and 
therapeutic index of hemolysis (TIH) have been previously published.69,98 Three independent trials 
were conducted for each circuit. The results of a second control (Medtronic Biomedicus BP-50, 
Minimax, and Medtronic Bio-Medicus Cannulas) are also included and methods have been 
previously described by our group.69 This second control, BP-50 control, was operated at the blood 
flow rate required for the Minimax to meet our 70 mL/min CO2 removal target. 
2.3 Results 
2.3.1 Model and In Vitro CO2 Removal 
In vitro gas transfer results and model predictions 0.65-m2 bundle are shown in Figure 2. 
The CO2 removal rate increased with increasing blood flow rate. The maximum CO2 removal rate 
of the LF-PAL was 105 ± 9.2 mL/min at a blood flow rate of 703 mL/min. The model predicted 
CO2 removal rates were within 7.7 – 15.4% of the experimental values.  
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Figure 2 LF-PAL In Vitro and Model Predicted CO2 Removal Rate 
The maximum CO2 removal rate for the LF-PAL was 105 mL/min. The model predicted the performance 
between 7.7 – 15.4% of the in vitro results 
2.3.2 Pump Performance 
The pressure generated by the 0.65 m2 LF-PAL device is shown in Figure 3. The pressure 
requirements for operation with the 15.5 Fr dual lumen catheter are also shown in Figure 3. The 
0.65 m2 LF-PAL reached the required flow rate range of 250 to 700 mL/min at impeller rotation 
rates between 800 and 1800 RPM.  
















L F -P A LM o d e l  P re d ic t io n
25 
 
Figure 3 Pump Performance of the LF-PAL 
The pressure generated by the LF-PAL at impeller rotation rates of 800, 1000, 1200, 1400, 1600, 1800 and 
2000 RPM between 0 and 1 L/min. The pressure requirements of the 15.5 Fr dual lumen catheter are also 
shown 
 
Typical CFD results shown in Figure 4 for the 0.65 m2 LF-PAL demonstrate adequate 
pressure generation and uniform flow distribution throughout the bundle. Generated pressure 
heads predicted by CFD were 51 mmHg for 850 RPM, 0.25 L/min and 265 mmHg for 1870 RPM, 
0.70 L/min. The maximum shear stress predicted by CFD in the device for these operating 
conditions was located on the rotor surfaces and was less than 200 Pa. Flow through the fiber 
bundle was shown to have a very uniform distribution and exhibited no flow separation. For both 
operating conditions, the LF-PAL was shown to have the slowest flow occurring in the inflow 
elbow and the bundle inlet and outlet plenums. 
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Figure 4 CFD Analysis of the LF-PAL 
CFD analysis results for 850 RPM and 0.25 L/min showing (A) predicted pressure (mmHg) throughout the 
device, (B) fluid velocity (m/s) thorugh the fiber bundle, and (C) near wall velocity magnitudes (m/s) on the 
device surfaces 
 
2.3.3 In Vitro Hemolysis 
Table 2 provides the TIH and NIH values for the 0.65 m2 LF-PAL and control circuits. The 
rate of pfHb increase over time was linear (R2 > 0.90) for the LF-PAL and control circuit. The TIH 
of the LF-PAL (0.08 ± 0.017 g/100min), the Pedimag control (0.043 ± 0.0004 g/100 min) and the 
BP-50 control (0.123 ± 0.013 g/100min) all significantly differed from one another (p<0.05). The 
NIH of the LF-PAL (0.158 ± 0.034 g/100 L), the Pedimag control (0.029 ± 0.003 g/100 L) and the 






Table 2 In Vitro Hemolysis of the LF-PAL 
Device 
Flow Rate NIH TIH 
[mL/min] [g/100 L] [g/100 min] 
LF-PAL (0.65 m2) 500 0.158 ± 0.034† 0.080 ± 0.017‡ 
Pedimag Control 1500 0.029 ± 0.003† 0.043 ± 0.004‡ 
BP-50 Control 1250 0.105 ± 0.012† 0.123± 0.013‡ 
†,‡ Statistically significant (p < 0.05) compared to other devices 
 
2.4 Discussion 
Clinical evidence demonstrates that ECCO2R can prevent the need for intubation, allow 
for protective and ultra-protective lung ventilation, and aid in weaning patients from mechanical 
ventilation.17,106 Low-flow ECCO2R devices aim to provide minimally invasive, complementary 
treatment options for ae-COPD patients and patients with moderate ARDS requiring mechanical 
ventilation. This manuscript details the in vitro and computational characterization of the LF-PAL 
for ECCO2R. The LF-PAL is an integrated pump-lung designed to allow simplified patient 
ambulation while on ECCO2R. The LF-PAL removed up to 105 mL/min of CO2 thereby exceeding 
the 70 mL/min target and had acceptable hemolysis.  
ECCO2R has been applied to a variety of clinical applications including weaning patients 
from mechanical ventilation, avoiding intubation and permitting lung protective 
ventilation.18,32,40,90,91 As a result of the range of clinical applications, the CO2 removal rate 
required for ECCO2R is not well defined.  Additionally, CO2 removal is dependent on the total 
CO2 content of the blood. Hence, the degree of hypercapnia will affect the CO2 removal rate at a 
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given blood flow rate. The CO2 removal rate, however, will proportionally increase with increases 
in pCO2. The CO2 removal target must therefore be reported as a percentage of the rate of 
metabolically produced CO2 or the pCO2 of the blood entering the device must be specified. 
Trahanas et al. provide a review of studies since 2009 of ECCO2R used in hypercapnic COPD 
patients and CO2 removal rates ranged from 80-160 mL/min.
44 From this the authors proposed that 
an ambulatory ECCO2R device must remove at least half of the metabolic CO2. Under 
normocapnic conditions this would be approximately 100 mL/min.  Commercial ECCO2R devices 
report removal rates of 20 – 40% of the metabolically produced CO2.
35–37 Under normocapnic 
conditions these rates are equal to 40 – 80 mL/min. Based on this data we set 70 mL/min as the 
minimum target CO2 removal rate for the LF-PAL at normocapnia. The LF-PAL exceeded this 
target at low-flow ECCO2R blood flow rates. Recent, on-going and upcoming ECCO2R clinical 
trials (XTRAVENT18, REST (ClinicalTrials.gov Identifier: NCT02654327), SUPERNOVA 
(ClinicalTrials.gov Identifier: NCT02282657), and VENT-AVOID (ClinicalTrials.gov Identifier: 
NCT03255057)) should provide a more defined CO2 removal target for devices in development. 
Concerns with low-flow ECCO2R, compared to mid-flow, include inadequate CO2 removal 
and thrombus formation resulting from low velocity regions within the device.97 To mitigate both 
of these effects the LF-PAL uses a fiber bundle with a narrow cross sectional area to increase local 
blood velocities and achieve clinically significant CO2 removal. In addition, CFD results of the 
LF-PAL demonstrate uniform blood velocity through the bundle. Other low-flow devices use 
active mixing technology to increase local blood velocity in an effort to achieve the required CO2 
removal rates. The Hemolung incorporates a rotating core38 and the ULFED uses rotating 
impellers.69 The drawback is that too high of an increase in blood velocity may detrimentally 
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increase hemolysis. The Hemolung, however, has been used in humans without causing clinically 
significant hemolysis, though no in vitro hemolysis data are available for comparison.41  
At least one center has begun ambulating ECCO2R patients to reduce muscle 
deconditioning and allow for greater physical therapy.90 A compact device which does not require 
a saline infusion or vacuum pump, such as the LF-PAL, that could also be worn would simplify 
ambulation. Current, clinically used ECCO2R devices are portable, but are not designed to be worn 
by the patient.39,107,108,31,109 The jugular cannulation and cartridge design of the Hemolung RAS 
permits ambulation. The device however must reside on the roller cart, which houses the required 
saline infusion and gas side vacuum pump, and does not provide the option to be worn by the 
patient. The Arterio-Venous CO2 Removal (AVCO2R) device is also under development as a 
wearable ECCO2R device.
110(p2) The AV-cannulation of the AVCO2R, however, relies on the 
patient’s cardiovascular system to drive blood flow. The CO2 removal rate is therefore dependent 
on the cardiac function of the patient.30 The VV-cannulation and pump-driven blood flow of the 
LF-PAL allows the clinician greater control of the extracorporeal blood flow and, in turn, the CO2 
removal rate. The compact design and dual lumen cannulation of the LF-PAL lends itself to 
ambulation. 
In this study the hemolysis of the LF-PAL was only evaluated at 500 mL/min. Shear stress 
within the circuit will increase as blood flow increases and likely result in elevated hemolysis at 
higher blood flow rates. Thus, when the LF-PAL is operated at the maximum blood flow rate, 700 
mL/min, the TIH of the LF-PAL will likely increase, as would the TIH of the control circuit when 
operated at a higher blood flow rate. A limitation to the TIH is the lack of an established threshold 
value correlated to clinically significant hemolysis in vivo. Thus, in vitro studies are limited to a 
comparative assessment between two circuits. Future in vivo studies will thoroughly evaluate if 
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the hemolysis generated by the LF-PAL is clinically significant in addition to any effect the device 
may have on platelet activation or end organ function. 
2.5 Conclusion 
Evidence demonstrating the benefits of partial CO2 removal by ECCO2R systems in 
conjunction with non-invasive ventilation or lung protective ventilation continues to grow. The 
LF-PAL provides the CO2 removal benefits of low-flow ECCO2R in a compact design. Future 
work will focus on 7-day in vivo studies to further characterize the LF-PAL performance and the 
effect of the device on the cardiopulmonary system. 
 
31 
3.0 The Effect of Hematocrit on the CO2 Removal Rate of Artificial Lungs 
The following chapter has been submitted for peer-review in the American Society for 
Artificial Internal Organs Journal 
3.1 Introduction 
Patients with moderate acute respiratory distress syndrome (ARDS) and acute 
exacerbations of COPD (ae-COPD) can benefit from lower tidal volume, lung protective 
ventilation or non-invasive ventilation strategies.17,18,40,90,91 These ventilation strategies can 
prevent ventilator-induced lung injury, however failure is commonly due to hypercapnia and the 
resulting acidosis and dyspnea.25 Low-flow extracorporeal CO2 removal (ECCO2R) devices have 
been utilized in this patient population to remove the excess CO2 while maintaining lung protective 
or non-invasive ventilation.18,32 ECCO2R devices operate on analogous principles to 
extracorporeal membrane oxygenation. Due to the primary objective of removing CO2 rather than 
oxygenation, ECCO2R devices can operate at blood flow rates below 1 L/min.
96 The potential 
benefits of ECCO2R are currently being evaluated in the VENT-AVOID and REST clinical trials. 
ECCO2R device selection and operating parameters dictate the CO2 removal rate (vCO2) but the 
nuances of CO2 removal can make interpreting changes in vCO2 challenging. Correct 
interpretation is especially important as vCO2 is the most sensitive indicator of intrabundle 
thrombosis.111 
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The vCO2 of a specific artificial lung geometry is a known function of blood flow rate, 
inlet pCO2, and sweep gas flow rate. The effect of extracorporeal blood flow rate and inlet pCO2 
on vCO2 can be taken into account by normalizing the vCO2 to these parameters.
112 The effect of 
sweep gas flow rate on vCO2 and the importance of a sweep gas independent regime has also been 
well established.113 Diminished vCO2 performance, however, has also been noted in animal studies 
during periods of anemia.114,115,116 The relationship between vCO2 and hematocrit (HCT) seen in 
artificial lungs has been attributed to mechanisms analogous to those within the native lungs. 
Bidani and Crandall used computational modeling to demonstrate that a decrease in HCT from 
45% to 15% results in a 50% decrease in vCO2 within the native lungs.
116 A similar vCO2-HCT 
relationship has been noted in animal studies,114 however the complexities of animal studies makes 
isolating the artificial lung vCO2-HCT relationship challenging.  
In this study we evaluated the relationship between HCT and the vCO2 of a low-flow 
ECCO2R device in an in vitro setting. Blood was hemodiluted with saline and plasma to reach the 
targeted HCT in order to evaluate any effect plasma proteins may have on vCO2. The in vitro 
setting allowed the effect of HCT and plasma proteins on vCO2 to be isolated. The results of this 




3.2.1 In Vitro Gas Exchange 
Bovine blood was collected from a local slaughterhouse and was heparinized (30 IU/mL), 
filtered (40 μm Pall Biomedical, Inc., Fajardo, PR), and treated with gentamicin (0.1 mg/mL). 
Blood was diluted to HCT levels of 8, 15, 25, and 33 ± 2 % with either isotonic saline (0.9% (w/v) 
Aqueous, Isotonic Saline, Fisher Scientific) or plasma. Plasma was obtained by centrifuging the 
whole bovine blood (2819 g for 15 min) and removing the plasma layer. 
Gas exchange testing followed the ISO7199 standard101 with the exception of the 
intentional alterations in HCT levels. The test circuit (Figure 1) included the ModELAS artificial 
pump-lung (0.65 m2 HFM bundle)112, two 6-L blood reservoir bags, and an Affinity oxygenator 
(Medtronic, Minneapolis, MN). The reservoir bags were submerged in a water bath to maintain a 
blood temperature of 37 ± 1 °C. The Affinity oxygenator was used to condition the blood to venous 
blood gas tensions (sO2 = 65 ± 5%, pCO2 = 45 ± 5 mmHg). Once the blood reached venous 
conditions, tubing clamps were manipulated so that blood was drawn from the venous conditioned 
reservoir, through the device, and returned to the second reservoir. Samples for blood gas 
measurements were taken immediately before and after the ModELAS. A RapidLab 405 blood gas 
analyzer was used to measure gas tensions (Siemens, Deerfield, IL). The CO2 removal rate, 
hemoglobin concentration and plasma protein concentration were measured at each HCT level in 
triplicate. 
The pump speed was adjusted to achieve 500 mL/min of blood flow through the ModELAS 
device. Blood flow rate was measured using an ultrasonic flow probe (Transonic Systems Inc., 
Ithaca, NY). The pure oxygen sweep gas flow rate (Q
SG
) was set to 14 L/min using a gas flow 
34 
controller (Fathom Technologies, Georgetown, TX). From preliminary experiments this sweep gas 
flow rate is within the sweep gas independent regime. CO2 concentration (FCO2) was measured in 
the exhaust sweep gas using a WMA-4 gas analyzer (PP Systems, Amesbury, MA). The CO2 
removal rate was calculated and normalized (vCO2
*
) to an inlet pCO2 of 45 mmHg according to 















An additional 4 mL blood sample was drawn from the device inlet to measure HCT and 
plasma protein each time a CO2 removal measurement was taken.  HCT was measured using a 
capillary tube which was spun down for 3 minutes in a micro-centrifuge (International Equipment 
Co., IEC MB, Needham Hts, MA). The remaining blood was centrifuged for 15 minutes at 0.8 g, 
the supernatant plasma was removed and centrifuged again at 7.2 g for 10 minutes. The plasma 
protein concentration was measured using a refractometer (TS 400, Reichert, Depew, NY) from 
this purified plasma. 
3.2.2 Statistical Analysis 
Data is reported as the mean ± standard deviation. Statistical analysis was completed in 
SPSS (IBM, Armonk, NY). A two-way repeated measures ANOVA was used to evaluate the effect 
of dilution method and HCT level on measured vCO2 and plasma protein concentration. Pairwise 
comparisons were made using Bonferroni post-hoc analysis. Statistical significance was 
determined at p < 0.05.  
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3.3 Results 
In vitro vCO2 for plasma and saline diluted blood are shown in Figure 5. There was no 
significant effect of dilution method (plasma dilution or saline dilution) on vCO2 (p = 0.427). The 
CO2 significantly decreased with decreasing hemoglobin concentration in a nearly linear fashion 
for both saline dilution (R2 = 0.998) and plasma dilution (R2 = 0.984). Decreasing the HCT from 
33% to 8% resulted in a 32% and 42% decrease in vCO2 when diluted with plasma and saline, 
respectively. The plasma protein concentration (Figure 6) decreased significantly after each 
hemodilution with saline (p = 0.00) and was significantly different between plasma and saline 
dilution (p<0.05).   
 
Figure 5 CO2 Removal Rate of Blood Diluted With Saline or Plasma 
The CO2 removal rates were measured at hematocrit increments of 8, 15, 25, and 32 ± 2 % in blood diluted 
with saline or plasma. The blood flow rate through the device was held constant at 0.5 L/min. 
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Figure 6 Plasma Protein Concentration after Dilution with Saline or Plasma 
Hemodilution with saline significantly decreased the plasma protein concentration at all hematocrit levels 
(p<0.05). 
3.4 Discussion 
The evidence supporting the use of ECCO2R to permit non-invasive or lung protective 
ventilation strategies in moderate ARDS and ae-COPD patients continues to increase. With this 
comes a need to identify variables which influence the vCO2 of artificial lungs, especially since a 
decrease in vCO2 can be indicative of intrabundle thrombosis.
111 The vCO2 of an artificial lung 
can be affected by blood and sweep gas flow rates, and the inlet pCO2 of the blood.
112,113 The effect 
of HCT on CO2 transfer has been documented in computational studies within the native lungs but 
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only observationally noted in artificial lungs during in vivo studies.114 This in vitro study evaluated 
the vCO2 within an ECCO2R device in blood diluted to multiple HCT levels using plasma and 
saline. In vitro testing demonstrated that the vCO2 linearly and significantly decreased with 
decreasing HCT level. CO2 removal rate was not affected by the method of hemodilution.  
CO2 transfer decreases with decreases in HCT within artificial lungs, as demonstrated here, 
as well as within the native lungs.115–118 The vCO2-HCT relationship within the native lungs has 
been attributed to 1) decreased buffering capacity provided by hemoglobin, 2) reduced flux of 
HCO3
-
 across the red blood cell (RBC) membrane, and 3) the release of fewer Bohr protons.116 The 
first two mechanisms are a direct result of fewer RBCs. Carbonic anhydrase (CA) within the RBC 
plays an integral role in rapidly hydrating CO2 via the catalysis of CO2 + H2O 
CA
⇔ HCO3
- + H+. 









, the chloride shift, to prevent 
the rate-limiting accumulation of HCO3
-
 within the RBC. These two mechanisms prevent the 
accumulation of H+and HCO3
-
 within the RBC which shifts equilibrium to the right. Reductions in 
hemoglobin and RBC concentration diminishes the buffering capacity and the surface area 
available for the chloride shift to occur. Thus, the reaction reaches equilibrium sooner and less 
CO2 is combined with blood per increase in pCO2. The third mechanism is the classic Haldane 
effect whereby the uptake of oxygen by hemoglobin in the lungs decreases the affinity of 
hemoglobin for CO2 and results in the release of H
+ and bound CO2. The released H
+ drives the 
equilibrium of the reaction to the left, towards dissolved CO2. Although less than 5% of the total 
CO2 content within blood is transported bound to hemoglobin, this source accounts for 30% of 
exhaled CO2.
26 Bidani and Crandall utilized a computational model to isolate each of these 
mechanisms and demonstrated that 50 – 60% of the decrease in vCO2 due to decreased HCT is 
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attributable to the third mechanism.116 Thus, even moderate decreases in HCT will result in 
decreased CO2 removal. These three factors result in anemic blood dissociating with less CO2 per 
decrease in pCO2. This essentially results in a flattening of the CO2 dissociation curve as the HCT 
level decreases.115 The above three mechanisms are inherent to properties of the blood, and not of 
the native lungs. Thus, these mechanisms are likely identical to those influencing the vCO2-HCT 
relationship within the artificial lung. 
The effects of anemia on CO2 exchange within the native lungs is often masked by 
compensatory mechanisms within the body. In this study, however, a 25% decrease in HCT led to 
a 13% decrease in vCO2. Normal gas exchange within the body is primarily maintained during 
periods of anemia by increases in cardiac output and ventilation rate, and changes to the 
microcirculation and metabolism.117 Within an artificial lung, decreases in HCT will result in 
increased extracorporeal blood flow rate if the pump speed is held constant, and would be 
analogous to increased cardiac output. In the present study, however, the pump speed was adjusted 
to maintain an extracorporeal blood flow rate of 500 mL/min as the HCT level was decreased. The 
other three compensatory mechanisms would not be mimicked within an artificial lung. Hence, 
even small changes to the HCT level impacted the vCO2 of the artificial lung during this study.  
The effect of plasma proteins was evaluated in the present study by comparing the vCO2 
of blood diluted with plasma versus that diluted with normal saline. Plasma proteins, mainly 
albumin and phosphates, typically contribute minimally to CO2 transport and CO2 removal. This 
is due to the ability of normal levels of hemoglobin to buffer approximately 6 times more H+ than 
plasma proteins are capable of.119 In anemic blood, however, the role of the buffering action of 
plasma proteins has been postulated to be more significant due to the reduced amount of 
hemoglobin.115 There was not a significant effect of dilution method (saline versus plasma) on 
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vCO2, even though there was a significant difference in plasma protein concentration at each HCT 
level between the two dilution methods. Arazawa, et al. report a similar in vitro result, whereby a 
miniature artificial lung only removed 13 mL/min/m2 more CO2 in a PBS+albumin solution than 
in a PBS solution.93 The results of the present study, and that of Arazawa, et al., demonstrate that 
the buffering capacity of plasma proteins is not significant enough to accommodate for the 
reduction, or absence, of HCT within an artificial lung. This is due to the CO2 carrying capacity 
of plasma being substantially due to the Cl
-
 shift which requires the presence of the RBC to 
occur.119 Thus, regardless of the nature of anemia (hemodilution versus diminished RBC 
production) an equivalent decrease in artificial lung vCO2 should be anticipated as HCT level 
decreases. 
In this study, as the blood was diluted the viscosity of the blood consequently also 
decreased. Extracorporeal blood flow rate was maintained at 500 mL/min by reducing the pump 
speed after each dilution. In an artificial lung, fluid viscosity (ν) affects the fluid boundary layer 
thickness at the fiber surface by ν1/6. The fluid side boundary layer provides the majority of the 
diffusional resistance to gas transfer within the artificial lung. Thus, with all else held constant, the 
gas transfer rate will increase as fluid viscosity decreases within an artificial lung.28 The results 
described within this manuscript do not make a distinction between increases in vCO2 due to a 
lower viscosity fluid and diminished vCO2 due to lowered HCT level.  
The interpretation of changes in vCO2 is only reliable if all factors influencing vCO2 are 
accurately accounted for. The results of this in vitro study provide evidence demonstrating that 
decreases in HCT result in decreased artificial lung CO2 transfer regardless of the nature of the 
anemia. Changes in the HCT must therefore be taken into account when determining the cause of 
changes in vCO2 within an artificial lung. 
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4.0 Chronic In Vivo Performance of the Low-Flow ModELAS 
The following chapter presents work submitted for peer-review in the Intensive Care 
Medicine Experimental Journal. Platelet activation studies were conducted by Sang-Ho Ye, PhD 
4.1 Introduction 
Mechanical ventilation (MV) has conventionally been used to normalize blood gas tensions 
in patients with acute respiratory distress syndrome (ARDS) or acute exacerbations of chronic 
obstructive pulmonary disease (ae-COPD). MV can further injure the lungs via ventilator-induced 
lung injury (VILI).2,89 VILI encompasses the resulting barotrauma, biotrauma and volutrauma 
from the high-volume ventilation, 10 – 15 mL/kg.120 Reducing the airway pressures through non-
invasive ventilation (NIV) or lung protective ventilation techniques can improve patient outcomes, 
however up to 25% of ae-COPD patients will fail NIV due to hypercapnia.19,20 The subsequent 
hypercapnia and acidosis require invasive MV to normalize blood gases.21,22 
Extracorporeal CO2 removal (ECCO2R) devices provide a means to manage CO2 levels in 
ARDS and ae-COPD patients while the source of the acute exacerbation is resolved. Protective 
and ultra-protective lung ventilation (tidal volumes of <6 mL/kg or 3 mL/kg, respectively) in 
conjunction with ECCO2R has been used in the treatment of moderate ARDS.
17,18 ECCO2R has 
been utilized to allow ae-COPD patients to avoid invasive MV or intubation.40,90,91 Typical 
ECCO2R duration for ae-COPD patients is 7 days or less.
44 The on-going VENT-AVOID 
(ClinicalTrials.gov Identifier: NCT03255057) and REST (ClinicalTrials.gov Identifier: 
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NCT02654327) randomized clinical trials evaluate the application of VV-ECCO2R in ae-COPD 
and ARDS patients, respectively. 
We are developing the Modular Extracorporeal Lung Assist System (ModELAS) as a 
multi-functional respiratory assist technology designed to accommodate three levels of respiratory 
assist. The ModELAS is a highly compact, integrated pump-lung capable of being worn, or 
integrated on to a wheeled console. The device can be configured to provide pediatric or adult 
complete respiratory assist (oxygenation and CO2 removal), or adult low-flow ECCO2R. Selection 
of the cannula and HFM bundle size permits configuration for either pediatric or adult respiratory 
applications. The pediatric ModELAS utilizes a central cannulation and has been evaluated in 7-
day animals studies84,121 The adult complete respiratory assist application uses a dual lumen 
cannulation and is currently being evaluated in 30-day animal studies.83,122 
In the present study, we evaluated the 7-day in vivo performance of the low-flow ECCO2R 
ModELAS in an awake ovine model. The ECCO2R ModELAS utilizes a 0.65 m
2 cylindrical, 
stacked, uncoated polymethylpentene HFM bundle. Our previously reported ECCO2R device 
utilized an identical bundle.112 The primary difference between the previous and current version 
of the device are washout holes within the impeller. The targeted CO2 removal for this device is at 
least 35% of the metabolically produced CO2 (70 mL/min at normocapnia) at a blood flow of 500 
mL/min. Characterization of sustained device CO2 removal, thrombogenicity, and 




The ModELAS was evaluated for 7 days in healthy, 41.2 – 54 kg Suffolk sheep (n = 6) at 
the McGowan Institute for Regenerative Medicine’s Center for Preclinical Studies. The animal 
care and surgical protocol was approved by the University of Pittsburgh’s Institutional Animal 
Care and Use Committee. All animals received humane care. 
Venous and arterial pressure lines were placed in the left external jugular vein and carotid 
artery, respectively. These lines were secured at the vessel and tunneled underneath the skin. The 
right external jugular vein was exposed via a surgical cut down. The target pre-catheterization 
activated clotting time (ACT) was above 300 s (ACT-II, Medtronic, Minneapolis, MN) and was 
achieved with a 180 IU/kg heparin bolus. Additional 1000 – 2000 IU heparin boluses were 
administered to increase the ACT above 300 s if necessary. The right external jugular vein was 
cannulated with a 15.5 Fr dual-lumen catheter (ALung Technologies, Pittsburgh, PA). The catheter 
was advanced to the right atrial-superior vena cava junction. Catheter position was confirmed via 
fluoroscopy. The catheter was secured to the neck via sutures and further protected with a neck 
wrap. 
The primed ModELAS (4 IU/mL heparinized saline) was connected to the catheter and 
extracorporeal blood flow was initiated at 0.5 L/min. Pure oxygen sweep gas was initially set to 4 
L/min. The animal was recovered in the intensive care unit and wore the device in a modified 
backpack (Figure 7). The animal was tethered within a pen and able to freely stand, lay and move 
its head during the study. Prophylactic antibiotics were given every 8 hours (25 mg/kg cephazolin) 
and an analgesic (1 mg/kg flunixin megulmin) was administered as needed. Mean arterial pressure 
(MAP), central venous pressure (CVP) and heart rate were recorded hourly. ACT was measured 
at least every 8 hours post-operatively, and more frequently when heparin titration was required.  
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Figure 7 Study Animal Wearing the ModELAS 
 
CO2 removal rate (vCO2) was measured daily and is reported as the average of 10 minutes 
of data collected at a sampling frequency of 2 Hz. Reported vCO2 was collected at a sufficiently 
high sweep gas flow rate (Q
SG
) that the vCO2 was not a function of sweep gas flow rate. The vCO2 
was measured as the fraction of CO2 in the outlet sweep gas (Fco2) (WMA-4 Analyzer, PP Systems, 
Amesbury, MA). The CO2 removal rate (vCO2) was calculated according to equation 4-1 and 

















The inlet pCO2 (PCO2
Inlet) used to normalize the vCO2 is the average of the device inlet pCO2 
taken immediately before and after data collection (PCO2
Inlet). During periods of low HCT (below 
18%) device inlet pCO2 was only taken prior to data collection. 
Plasma free hemoglobin (pfHb), blood chemistry and complete blood count (CBC) were 
measured pre-operatively and post-operatively on pre-operative days 6 and 1, and on POD 0, 1, 3, 
6, and 7. The blood sampling schedule was modified if HCT was below 18% in order to reduce 
the number of blood draws. The reported pre-operative measurements are an average of data from 
both pre-operative days. POD 0 data is an average of samples taken when the arterial line was 
placed, initiation of extracorporeal blood flow and 4 hours post-operatively. PfHb and platelet 
activation were measured using previously described methods.102,123,124 Blood chemistry, manual 
platelet count and CBC were measured by an external lab (IDEXX Laboratories, Inc., Westbrook, 
ME). Liver and kidney function and tissue injury were monitored by aspartate transferase (AST), 
alanine transferase (ALT), alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine, 
and creatine kinase (CK). Platelet activation was measured via flow cytometry as previously 
reported.123,124 Platelet function was quantified by activating platelets with platelet activating 
factor (PAF). 
Blood chemistry, platelet count and CBC samples were not drawn on POD 6 for Trials 3 
and 6 due to low hematocrit. The blood chemistry for Trial 4, pre-operative day 6 and manual 
platelet count for Trial 6, preoperative day 1 and POD 1 and 3 were not measured due to a technical 
oversight. 
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4.2.1 Statistical Analysis 
Data points were averaged across studies for each POD and are reported as the average ± 
standard deviation. Statistical analysis was completed using IBM SPSS (IBM Corporation, North 
Castle, NY). Due to instances of missing data previously described, the statistical analysis was 
completed using a mixed linear model analysis of variance and the restricted maximum likelihood 
estimation method.125 Raw extracorporeal blood flow rate, motor torque, heart rate, CD62P 
expression, creatinine, CK, ALT and BUN data violated the assumption of normality based on the 
Kolmogorov–Smirnov test and were normalized126 prior to statistical evaluation. For those 
comparisons in which time had a significant effect, pairwise comparisons were conducted using 
least significant difference analysis. Statistical significance was considered at p<0.05.  
4.3 Results 
All animals were successfully recovered post-implant and five studies were electively 
terminated on POD 7. Trial 4 was terminated early on POD 4 due to low MAP and an elevated 
lactate level. The necropsy showed significant pulmonary emboli within both lungs. 
Histopathological examination of the pulmonary emboli demonstrated that the initial emboli likely 
occurred several days prior to the end of study. On POD 1 of Trial 4 the extracorporeal blood flow 
rate was 0.0 L/min for approximately 1 hour. The device inflow tubing was clamped off while 
saline was forced through the device outflow tubing and this returned blood flow to 0.5 L/min. 
Significant anemia was observed during Trial 3 due to a non-study related hematoma within the 
right scapular/axillary region. No thrombus or free fluid was evident within the chest or 
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pericardium, thus the scapular hematoma was likely due to accidental trauma to the shoulder. Trial 
5 was terminated approximately 3 hours prior to the planned end of study due to a fractured 
positive pressure port on the device used to measure bundle inlet pressure on the prototype device. 
Significant blood loss through the fractured port necessitated rapid euthanasia and POD 7 
bloodwork and gas exchange data was not collected.  
Figure 8 provides average extracorporeal blood flow rate and vCO2. Average blood flow 
rate across all trials was 0.48 ± 0.01 L/min and did not vary significantly over the course of the 7 
days (p = 0.338). Average CO2 removal (normalized to an inlet of 45 mmHg) across all trials and 
time points was 75.6 ± 4.7 mL/min. Daily average vCO2 did not vary significantly from POD 0 (p 
= 0.233).  The average device inlet pCO2 was 43.6 ± 1.1 mmHg. The device inlet pCO2 values 
measured before and after the vCO2 data collection did not deviate by greater than 15%. MAP, 
CVP, and heart rate did not significantly change from POD 0 (Table 3). Table 4 provides pre-
operative and post-operative animal hematologic parameters used to evaluate end organ function 
and hemocompatibility. Platelet function and activation did not statistically change from pre-
operative values. BUN statistically increased on POD 6 prior to returning to pre-operative values 
on POD 7. HCT post-operatively was statistically less than pre-operative measurements. Post-
operative pfHb remained below 25 mg/dL with the exception of POD 3 - 5 of Trial 2 prior to 
returning to a normal level on POD 7 (Figure 9). This animal showed signs of an acute kidney 
injury on POD 4 which resolved on POD 6. Macroscopic and microscopic examination showed 
no abnormalities or damage to the heart, lungs, liver, kidneys or spleen, except Trial 4 which 
exhibited signs of a pulmonary embolism.  
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The explanted device from Trial 2 had thrombus at the bottom pivot of the impeller and 
within the bundle (Figure 10). During this trial the ACTs were below the target range for a quarter 
of the study. All other explanted devices were free of significant thrombus. 
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Figure 8 Extracorporeal Blood Flow Rate and CO2 Removal Rate 
Daily extracorporeal blood flow rate (A) and normalized CO2 removal rate (B). When compared to POD 0 
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Table 3 Hemodynamic and Device Parameters 
  
  
POD 0 POD 1 POD 2 POD 3 POD 4 POD 5 † POD 6 † POD 7 † 
MAP[mmHg]  91 ± 5 91 ± 7 89 ± 7 93 ± 5 96 ± 8 104 ± 5* 100 ± 7* 96  ± 7 
CVP [mmHg] -1 ± 2 -2 ± 2 -2 ± 2 -2 ± 1 -1 ± 2 -3 ± 2 -1 ± 3 -2 ± 2 
HR [BPM]            94 ± 2 85 ± 13 92 ± 23 107 ± 25 124 ± 31* 111 ± 19 119 ± 27 119 ± 44 
Speed [RPM] 1208 ± 80 1212 ± 47 1223 ± 54 1231 ± 53 1225 ± 54 1228 ± 59 1227 ± 62 1227 ± 60 
Torque[mN-m]  10 ± 1 10 ± 1 10 ± 1 10 ± 1 10 ± 1 10 ± 2 10 ± 2 11 ± 3 









Table 4 Hematologic and End Organ Parameters 
 
 
Pre-op POD 0 POD 1† POD 3‡ POD 6§ POD 7||,** 
PAF Activated [%] 71 ± 9 70  ± 10 77  ± 11 72 ± 11 75 ± 12 76 ± 3 
CD62P [%] 3 ± 1 4 ± 2 2 ± 1 5 ± 5 5 ± 3 4 ± 2 
Platelet Count [k/μL] 576 ± 252 397 ± 110 499 ± 186 703 ± 281 520 ± 115 552 ± 198 
WBC [K/μL] 8.6  ± 3 6.7 ± 2 12.3 ± 4 11.5 ± 4 12.2 ± 5 11.9 ± 1.7* 
HCT [%] 36 ± 3 24 ± 2* 29 ± 2* 27 ± 6* 24 ± 4* 27 ± 7* 
End Organ Status 
Creatinine [mg/dL] 1 ± 0 1 ± 0 2 ± 1 3 ± 3 1 ± 0 1 ± 0 
BUN [mg/dL] 11 ± 2 11 ± 3 11 ± 5 27 ± 21 26 ± 16* 14 ± 4 
CK [U/L] 103 ± 23 155 ± 51 143 ± 72 71 ± 11 149 ± 88 126 ± 80 
ALT [U/L] 12 ± 5 9 ± 3 9 ± 4 5 ± 3 5 ± 2 5  ± 5 
AST [U/L] 71 ± 14 58 ± 11 73 ± 19 56 ± 10 53 ± 12 59 ± 9 
ALP [U/L] 218 ± 56 165 ± 55 158 ± 41 141 ± 33 101 ± 26 128 ± 64 
† Missing platelet count from Trial 6; ‡ Missing platelet count from Trials 2, 5, 6; § Missing all data, except HCT, for 
Trials 3, 4, 6; || Missing all data, except HCT, for Trials 4, 5; ** Missing CD62P and PAF Activated for Trial 3; 
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Figure 10 Explanted Bundle and Impeller 
Images of the explanted hollow fiber membrane bundle inlet (top row) and outlet (bottom row) faces and the 
(B) impeller top (top row) and bottom (bottom row) pivots. The Trial 2 (right) bundle and pivots had 




The Modular Extracorporeal Lung Assist System (ModELAS) is an integrated, modular 
pump-lung capable of providing three levels of respiratory assistance. Selection of the cannula and 
hollow fiber membrane bundle configures the ModELAS for pediatric complete respiratory assist, 
adult complete respiratory assist or adult low-flow CO2 removal. The adult and pediatric complete 
respiratory assist applications have been evaluated in animals for up to 7-days, and are currently 
undergoing 30-day animal studies.83,121,122 The present study evaluated the performance and 
hemocompatibility of the low-flow CO2 removal ModELAS in a healthy ovine model for 7 days. 
All animals were successfully recovered from the surgery and a single trial required early 
termination on POD 4. No device exchanges were required. 
Clinical evidence demonstrating the benefits of low-flow ECCO2R in ae-COPD and 
moderate ARDS patients continues to grow. The VENT-AVOID (ClinicalTrials.gov Identifier: 
NCT03255057) and REST (ClinicalTrials.gov Identifier: NCT02654327) randomized clinical 
trials aim to further expand the clinical evidence of using VV-ECCO2R as an alternative to invasive 
mechanical ventilation or in conjunction with low tidal volume ventilation, respectively. Lung 
protective ventilation, which utilizes low tidal volumes, can fail due to hypercapnia and require 
transitioning patients to invasive mechanical ventilation which is known to cause VILI. The CO2 
removal capabilities of ECCO2R can resolve the hypercapnia during lung protective ventilation, 
and in some instances allow extubation and NIV.17,18,40,90,91 In addition, the low extracorporeal 
blood flow rate of ECCO2R, typically less than 1 L/min, makes the technology less invasive 
compared to ECMO.  
The ModELAS was generally well tolerated by the animals. These preclinical studies 
indicate that the low-flow ECCO2R configured ModELAS can operate for 7 days without 
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diminished CO2R performance nor significant damage to blood or end organs. The average vCO2 
was 75.6 mL/min and the vCO2 on POD 7 was 83% of that on POD 0. Platelet and organ function 
parameters used to evaluate device safety did not significantly change during the study (Table 1). 
Except Trial 4, macroscopic and histopathological evaluation of the end organs did not indicate 
any device related pathology. Low HCT resulting from a shoulder hematoma (Trial 3), pulmonary 
embolism (Trial 4) and subcutaneous bleeding (Trial 5) resulted in slightly diminished CO2 
removal rates 116 and increased blood flow rates during the latter half of the study. Pre-operative 
pfHb samples were drawn via a venous puncture, and are therefore slightly elevated. A single 
study (Trial 2) had elevated pfHb measurements greater than the 40 – 50 mg/dL clinically relevant 
threshold 114,127,128. The maximum pfHb value occurred on POD 6 before decreasing on POD 7. 
The elevated pfHb was not associated with any hematuria. Trial 2 is also the sole trial in which the 
explanted device contained significant thrombus at the pivot bearing, likely caused by periods of 
improperly concentrated heparin infusion solutions. The thrombus and subsequent friction at the 
pivot bearing are a possible contributors to the elevated pfHb. In addition, just prior to this period 
of elevated pfHb the animal displayed symptoms of an acute kidney injury. The combination of 
the pivot thrombus and the kidney injury likely caused the sharp increase in pfHb in Trial 2. 
Elevated pfHb was isolated to one out of the six studies, rather than a trend, and is not indicative 
of significant safety concerns. 
The most significant device related adverse event was a pulmonary embolism during Trial 
4. This trial required early termination on POD 4 due to low MAP and elevated heart rate and 
blood lactate concentration. The root cause of these symptoms was an acute pulmonary embolism 
in both lungs. This thrombus initiated several days prior to the end of study based on 
histopatholigical examination of the thrombus organization. Thromboembolism is a known risk of 
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connecting any device to the vasculature including current artificial lungs129,130 and ventricular 
assist devices 131,132. In preclinical testing, the key is to differentiate whether the thromboembolism 
is inherent to the device design, or was independent of the device used. The densely packed hollow 
fiber membrane bundle of the ModELAS acts as a filter, hence it is unlikely that the thrombus was 
generated within the pump and migrated post-device. Thus, the precipitating thrombus likely 
originated between the outlet of the device and the cannula tip and was dislodged on POD 1 with 
the saline flush. The exact cause of the original thrombus remains unknown, however it does not 
appear to be characteristic of the device. The entire ModELAS circuit is also uncoated, whereas 
most commercial artificial lungs circuits are coated with a biocompatible coating.39,108 Our 
laboratory is currently developing a tip-to-tip zwitterionic surface coating which will further 
improve hemocompatibility and further deter any thrombosis within the ModELAS circuit.133 
The most relevant comparison to the ECCO2R ModELAS is the Hemolung RAS (ALung 
Technologies, Pittsburgh, PA) which is currently undergoing an FDA clinical trial (VENT-
AVIOD) to evaluate the use of the Hemolung RAS as an alternative or supplement to invasive MV 
in ae-COPD patients. The Hemolung RAS is also a part of the REST trial in the UK which is 
assessing the use of VV-ECCO2R in conjunction with lung protective ventilation in ARDS 
patients. The Hemolung utilizes a rotating core to induce active mixing within the annular bundle 
(0.59 m2). In pre-clinical healthy ovine studies, the Hemolung achieved 42 – 53 mL/min of CO2 
removal and blood flow rates between 350 and 450 mL/min.114 The ModELAS CO2 removal rate 
ranged from 69 - 84 mL/min at blood flow rates ranging between 430 – 590 mL/min. The improved 
vCO2 in the ModELAS could be a result of slightly higher blood flow rates and bundle surface 
area (0.65 m2). Neither the ModELAS nor the Hemolung had apparent adverse effects on 
hemodynamics or end organ function. The ModELAS performed comparatively to the Hemolung, 
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with the additional benefit of being designed as a wearable unit and capable of a wider range of 
therapies. 
4.5 Conclusion 
The ModELAS is a platform respiratory assist technology designed to provide adult or 
pediatric complete respiratory assist, or adult low-flow CO2 removal. The device has been 
extensively tested in vitro at all three respiratory assist levels83,84,112 and the complete respiratory 
assist applications have been evaluated in animals.121,122 This series of 7-day studies in healthy, 
awake sheep provides in vivo evaluation of the low-flow CO2 removal ModELAS. These studies 
demonstrated that the ModELAS can consistently remove a clinically relevant amount of CO2 
without causing detrimental effects on the animal. The ModELAS was well tolerated by the 
animals with only isolated device related events. In addition to developing a zwitterionic 
biocompatible coating to potentially afford reduction in the required anticoagulation133, future 
work involves developing the controller into a compact, wearable unit with incorporated feedback 
controls and an intuitive user interface. 
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5.0 Acute In Vivo Performance of the Pediatric ModELAS 
 The following chapter presents work peer-reviewed and published in the American Society 
for Artificial Internal Organs Journal. 
5.1 Introduction 
Chronic lung diseases such as cystic fibrosis, pulmonary hypertension and pulmonary 
fibrosis continue to be sources of pediatric morbidity and mortality. These patients often require a 
heart or heart-lung transplant, however the waitlist duration is typically 1 – 6 months.63 Mechanical 
ventilation (MV) and extracorporeal membrane oxygenation (ECMO) can be used to provide 
respiratory support to these patients as a bridge-to-transplant. Between 2009 and 2015, the number 
of pediatric extracorporeal respiratory support cases reported to the Extracorporeal Life Support 
Organization (ELSO) increased by 48% (569 cases in 2015).134 Both MV and ECMO however are 
often considered contraindications pre-transplant. MV can result in ventilator induced lung injury2 
and the complex circuitry of current ECMO devices can lead to complications. In one study, up to 
36% of the pediatric ECMO cases exhibited circuit complications.135  Recent advancements in 
ECMO therapy including polymethylpentene fibers, heparin coatings, centrifugal pumps and 
portability has led to the reevaluation of ECMO pre-transplant.136 
Recent efforts have focused on improving the portability of ECMO circuits in order to 
improve patient mobility. The immobilization of patients on MV or ECMO can lead to muscular 
deconditioning and poor post-transplant outcomes. Several centers have demonstrated improved 
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post-transplant outcomes in patients who were able to ambulate while on ECMO.71,72,75 One of the 
current barriers to ambulatory ECMO is the complexity of the ECMO circuit and need for a 
specialized, highly coordinated team effort during patient ambulation. Thus, current efforts aim to 
design ECMO units specific to pediatric needs that also allow for simpler and less risky patient 
ambulation within the hospital.  
We are currently developing the Pittsburgh Pediatric Ambulatory Lung (P-PAL) and its 
second generation device, the Pediatric ModELAS (P-ModELAS), as an ambulatory artificial lung 
for long-term respiratory support.84 The P-PAL improves compactness and decreases complexity 
by integrating the oxygenator and pump into a single wearable unit. The device could be worn by 
either the patient or a caregiver. In the present study, we evaluated the in vivo performance of the 
P-PAL in an acute ovine model. In vivo gas transfer and hemolysis were measured in addition to 
animal hemodynamics. Additionally, we developed and refined our surgical and cannulation 
strategy in preparation for chronic, recovery studies. 
5.2 Methods 
5.2.1 Device Description 
The P-PAL is an integrated pump-lung designed for respiratory support of pediatric 
patients and is ultimately intended to provide long-term (1 – 3 months) support. The device is 
intended to be operated at blood flow rates of 1 – 2.5 L/min and provide up to 90% of the 
respiratory support of 5 -25 kg children. This represents an oxygenation rate of 30 – 105 mL/min. 
Blood is drawn from the right atrium and pumped through a polymethylpentene HFM bundle (0.3 
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m2) by an integrated centrifugal pump. Oxygenated blood is then returned to the pulmonary artery 
via an arterial cannula. 
Two slightly different P-PAL design iterations were used during the acute trials. Trials 1 - 
4 used the previously described P-PAL design (subsequently referred to as P-PAL).84 Trials 5 and 
6 were conducted with a second generation design (P-ModELAS and shown in Figure 11). The P-
ModELAS centrifugal pump and HFM bundle are identical to that used in the P-PAL. The primary 
difference between the designs is a shortened blood flow channel leading from the pump 
compartment to the bundle compartment in the P-ModELAS. This change allows for easier 
priming and a more compact overall device. The priming volume of the P-ModELAS circuit was 
270 mL. Excess acrylic was also removed from the device housing in the P-ModELAS. This 
reduced the mass of the device from 1157 g to 721 g. The in vitro pump performance, gas transfer 
and hemolysis results of the P-PAL have been previously published.84 Benchtop pump and gas 
transfer performance were equivalent between the two versions. 
 
 
Figure 11 Schematic and Photograph of the P-ModELAS 
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5.2.2 Acute In Vivo Testing 
Animal hemodynamics, gas exchange performance, and biocompatibility were evaluated 
in an acute (4 – 6 hours) ovine model. Sheep (n=6) weight ranged from 23.3 to 32.2 kg. All trials 
were completed in the Center for Preclinical Studies at the McGowan Institute and all animals 
received humane care. The University of Pittsburgh’s Institutional Animal Care and Use 
Committee approved the protocol for animal care and surgery.  
Anesthesia was induced by a subcutaneous injection of atropine (0.05 mg/kg) followed by 
intravenous administration of ketamine (3.9 – 5.3 mg/kg). Animals were directly intubated with a 
cuffed Magill endotracheal tube. Anesthesia was maintained throughout the study via isoflurane 
inhalation (1.5 – 3 %) to effect. An arterial line was placed in the carotid artery to monitor mean 
arterial pressure (MAP). A venous line was placed in the jugular vein to monitor central venous 
pressure (CVP) and provided access for maintenance drips. Access to the right atrium and 
pulmonary artery was made via a right (Trials 1 – 2) or left (Trials 3 – 6) thoracotomy. A pressure 
monitoring line was placed in the pulmonary artery (Trials 2 – 6) to monitor pulmonary artery 
pressure (PAP). Heart rate, MAP, CVP and PAP were recorded every 15 minutes. Prior to cannula 
placement a heparin bolus (300 IU/kg) was administered to increase the activated clotting time 
(ACT) to greater than twice baseline to prevent clot formation in the cannulas prior to starting the 
pump. The venous cannula was placed in the right atrium and the arterial cannula was placed in 
the pulmonary artery. The ACT target for the duration of the study was 1.5 – 2 times baseline. 
Heparin was continuously administered through the venous line and the infusion rate periodically 
altered to maintain the target ACT range.  
The cannulas were connected to a primed (1 IU/mL heparinized saline) P-PAL device. 
After the P-PAL pump was started and flow initiated, a stabilization period of at least 10 minutes 
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was permitted prior to the commencement of gas exchange sampling. A 5% CO2 95% O2 sweep 
gas mixture was set to 3 – 5 L/min. The P-PAL impeller rotation rate was varied in order to attain 
each targeted blood flow rate (1.0, 1.5, 2.0, 2.5 L/min) during three repeated measurements. Blood 
gas tensions and hematocrit were measured from device inlet and outlet samples. Plasma free 
hemoglobin was measured from blood samples taken from the arterial line. Methods for 
spectrophotometrically measuring plasma free hemoglobin have been previously published.102 
Additional blood samples were routinely taken from the arterial line in order to monitor the 
animal’s arterial blood gas tensions, electrolytes and hematocrit. Ventilator settings (FiO2, PEEP 
and rate) were adjusted to maintain normal physiologic arterial blood gases. Pressure drop across 
the bundle was measured continuously (PCU-2000, Millar, Texas).  
At the completion of the study, the heart and lungs were examined for gross abnormalities. 
The device was disconnected and saline was passively flowed through the device to wash away 
blood while preserving any intra-device thrombus. The device was disassembled, and any 
thrombus formation was noted. The inlet and outlet faces of the HFM bundle were photographed. 
5.2.3 Statistical Analysis 
Statistical analysis was conducted in SPSS (IBM, Armonk, NY). Results are reported as 
an average and standard deviation. The baseline and final MAP, CVP and heart rate were compared 
using a paired samples t-test per animal. The baseline MAP, CVP and heart rate are an average of 
vital signs recorded during the 30 minutes prior to initiation of device blood flow. The final MAP, 
CVP and heartrate are an average of the vital signs taken during the final hour of the study. Vital 
signs were recorded every 10 – 15 minutes. Statistical analysis was not performed on the PAP due 
to a lack of repeated measurements. A two-way ANOVA was used to evaluate the effect of device 
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type (P-PAL versus P-ModELAS). Differences were considered statistically significant for p < 
0.05. 
5.3 Results 
All studies were electively terminated following the completion of data collection. Table 5 
provides a comprehensive summary of each trial. The ACT range throughout the studies was 1.2 
– 4.1 times baseline. The blood flow rate range for Trial 2 was limited to 1.0 – 1.4 L/min due to a 
venous cannula occlusion resulting in suction and limited blood flow at higher impeller rotation 
rates. The necropsy following Trial 2 revealed right atrium bruising indicative of cannula suction 
at the right atrium wall. Subsequent trials utilized a right thoracotomy to gain improved access to 
the heart and placement of the cannula at the main wall of the right atrium. In Trial 4, thrombus 
formed in the HFM bundle and subsequently led to decreased oxygen transfer and device blood 
flow rate. The bundle resistance increased from 11 mmHg/L/min to 120 mmHg/L/min by the end 
of the study. Visual inspection of the bundle showed thrombus formation within ~25% of the 
bundle (Figure 12). All other trials were completed without complication. 
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Table 5 Summary of Acute Pediatric Trials 
Trial 
No. 







18 Fr Straight (ven)1 
Left Thoracotomy P-PAL 1.0-2.5 4.5 - 
16 Fr Straight (art)2 
2 
22 Fr Right Angle (ven)3 
Left Thoracotomy P-PAL 1.0-1.4 4 
Flow Limitation  
16 Fr Straight (art)2 (ven cannula occlusion) 
3 
22 Fr Right Angle (ven)3 
Right Thoracotomy P-PAL 1.0-2.5 6 - 
16 Fr Straight (art)2 
4 
22 Fr Right Angle (ven)3 
Right Thoracotomy P-PAL 1.0-2.4 6 
Device Failure  
16 Fr Straight (art)2 (↑ bundle resistance) 
5 
22 Fr Right Angle Metal Tip (ven)4 
Right Thoracotomy P-ModELAS 1.0-2.5 6 - 
18 Fr Straight (art)5 
6 
22 Fr Right Angle Metal Tip (ven)4 
Right Thoracotomy P-ModELAS 1.0-2.5 6 - 
18 Fr Straight (art)5 
1Medtroni DLP Single Stage Venous Cannula (#66118) 2Medtronic DLP One-Piece Arterial Cannula (#77016) 3Edwards 
Lifesciences Thin-Flex Single Stage Venous Drainage Cannula (VCS02290) 4Medtronic DLP Single Stage Venous Cannula 
(#69322) 5Medtronic Elongated One-Piece Arterial Cannula (EOPA) (#77518) 
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Figure 12 Photographs of a Explanted Bundle Faces 
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A maximum oxygen transfer rate of 83.7 ± 3.5 mL/min was achieved at 2.5 L/min (Figure 
13). The average hemoglobin concentration across all trials was 6.2 ± 0.3 g/dL and the blood 
exiting the device was 100% saturated at all blood flow rates for all trials except Trial 4. There 
was no significant effect of device type (P-PAL versus P-ModELAS) on oxygenation rate 
(p>0.05).  
Plasma free hemoglobin remained below 20 mg/dL for all trials (Figure 14). Post-study 
macroscopic inspection of the device flow paths, bearings and bundle revealed an absence of any 
significant thrombus for all trials except Trial 4. Figure 12 provides representative post-study 
photographs of the bundle inlet and outlet faces. 
Table 6 summarizes animal hemodynamics at baseline (prior to cannulation) and at the end 
of the study. Heart rate was not affected by the device (p > 0.05) during any of the trials. MAP 
statistically decreased (p < 0.05) in Trial 2 (89 ± 5 mmHg to 64 ± 10 mmHg) and increased in Trial 
3 (52 ± 6 mmHg to 58 ± 4 mmHg). CVP statistically decreased (p < 0.05) in Trial 4 (11 ± 2 mmHg 
to 7 ± 1 mmHg) to the average CVP of this series of studies. With the exception of cannula-related 




Figure 14 In Vivo Plasma-Free Hemoglobin Generated by the P-PAL 
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Table 6 Baseline and Final Animal Hemodynamics 
  MAP CVP Heart Rate PAP 
  [mmHg] [mmHg] [beats/min] [mmHg] 
Trial 
No. 
Baseline Final Baseline Final Baseline Final Baseline Final 
1 65 ± 5 54 ± 1.0   9 ± 2 9 ± 1   95 ± 13 88 ± 2     --     --   
2 89 ± 5 64 ± 10*   8 ± 1 5 ± 1   81 ± 5 80 ± 1    17   18 ± 1   
3 52 ± 6 58 ± 4*   6 ± 2 4 ± 1   94 ± 4 97 ± 2    18   21 ± 2   
4 62 ± 14 53 ± 5   11 ± 2 7 ± 1*   93 ± 5 95 ± 8    11   11 ± 1   
5 68 ± 15 49 ± 6   7 ± 2 5 ± 1   89 ± 15 102 ± 5    14   17 ± 1   
6 61 ± 21 41 ± 1   5 ± 4 10 ± 1   92 ± 19 95 ± 1    12   15 ± 2   
*p<0.05, considered significant between baseline and final values                             
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5.4 Discussion 
MV and ECMO are the primary treatment options for pediatric patients with lung failure. 
These treatments, however, greatly restrict patient mobility and MV can further lung injury. The 
ability to mobilize ECMO patients and increase their participation in physical therapy pre-
transplant has been shown to improve post-transplant outcomes.71,72,75 The P-PAL is specifically 
designed as a wearable, long-term respiratory assist device. The integration of the pump and 
oxygenator into a highly compact unit creates a less complex circuit to allow simplified, in-hospital 
patient ambulation. Previous in vitro work has demonstrated sufficient pumping, gas exchange, 
and hemolysis performance.84 The present study used a healthy ovine model to evaluate the acute 
in vivo performance of the P-PAL as well as develop an optimal implantation strategy. Results 
demonstrated successful performance of the P-PAL in an acute support setting and established the 
surgical and implantation techniques needed for chronic, recovery studies. 
Current pediatric ECMO devices are multicomponent systems connected via lengths of 
tubing. These complex and cumbersome circuits require highly trained teams during patient 
ambulation and the risk of device or circuit malfunction is elevated. Thus, current research efforts 
have shifted toward the development of compact respiratory support systems that could be worn 
paracorporeally and enable patient mobility. The University of Maryland is developing the 
Pediatric Pump Lung (PediPL) as an ambulatory ECMO device.82,137 The PediPL integrates a 
centrifugal pump utilizing a magnetically levitated impeller with an annular HFM bundle. The 
PediPL has exhibited positive in vitro and in vivo results but has not progressed to clinical use as 
of yet. These efforts highlight the need for ambulatory respiratory support devices and the 
importance of the continued development necessary for their safe and effective use in patients. 
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The P-PAL demonstrated consistent oxygenation and pumping performance in an acute 
support setting. Blood flow limitation due to venous cannula inlet occlusion during Trial 2 led to 
a modified cannula placement technique via a right thoracotomy. In all subsequent trials, the P-
PAL was able to generate the full range of targeted blood flow rates (1 – 2.5 L/min). The P-PAL 
device used during Trial 4 developed diffuse intra-bundle thrombus during the study duration. The 
thrombus formation resulted in progressive bundle resistance increase and oxygen transfer 
decrease during support. This was an isolated occurrence and is suspected to have originated from 
inadequate device priming prior to the implant. Previous computational work has predicted 
spatially uniform blood flow through the P-PAL HFM bundle84 and all other trials in the current 
work resulted in an HFM bundle remarkably free of thrombus. With the exception of Trial 4, the 
P-PAL achieved full blood oxygen saturation at all evaluated blood flow rates. In vivo oxygen 
transfer rates were limited by low hemoglobin concentrations and thus are not representative of 
the full oxygenation capability of the device. The intraoperative anemia observed in these acute 
studies is not uncommon and likely attributable to hemodilution and perioperative red blood cell 
sequestration. A return to more normal hemoglobin concentrations in the days following surgery 
is expected during longer-term P-PAL studies. As expected, there was no discernible difference in 
device performance between the two slightly different P-PAL design iterations used in this study. 
The evolution of the design was driven by a goal to attain a lighter device (P-ModELAS was 436 
g lighter) that was easier to prime.  
P-PAL support was generally well tolerated and exhibited minimal effects on normal 
physiological function. Although statistically significant changes in MAP and CVP occurred in 
some trials, no consistent or concerning trends were observed. Hemolysis was low during P-PAL 
support with plasma free hemoglobin concentrations remaining generally constant throughout 
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support and well below 20 mg/dL. Outside of one incident of slight bruising at the right atrium 
attributed to cannula suction, the native heart and lungs were free of gross abnormalities resulting 
from the device at the time of necropsy. 
 Surgical and cannulation methods were refined throughout this series of acute studies and 
led to an optimized implantation strategy to be used during longer-term recovery studies. Changing 
from a left to right thoracotomy allowed for better placement of the cannula into the main wall of 
the right atrium. The later trials using this approach (Trial 3 – 6) were free of complications arising 
from cannula suction within the right atrium. The cannulas used in Trials 5 and 6 enabled even 
further increased venous drainage and will ease tunneling of the cannulas during future chronic 
studies. Based on this series of acute studies, the cannulation strategy for upcoming long-term 
recovery studies will utilize a right thoracotomy to place a 22 Fr right angle venous cannula into 
the RA and an 18 Fr arterial cannula into the PA.  
Although the Avalon DLC has popularized peripheral cannulation in adult ECMO patients, 
pediatric patients present unique challenges which may benefit from a central cannulation. A 
central cannulation is often preferred in pediatric patients due to concerns with patient cooperation, 
availability of appropriate cannula sizes and blood recirculation between the cannula inlet and 
outlet. Maeda et al. have recently published two cases where long-term pediatric ECMO patients 
initially cannulated peripherally required recannulation centrally.80  
5.5 Conclusion 
The P-PAL is a compact, integrated pump-lung designed for ambulatory respiratory 
support in children. Acute in vivo evaluation of the devices confirmed the sufficient gas transfer, 
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pumping and hemolysis performance demonstrated during benchtop studies. Additionally, acute 
respiratory support with the P-PAL using the final implant strategy showed no adverse effects on 
animal hemodynamics or the native cardiopulmonary system. Future work includes 7- and 30-day 
sheep studies to further characterize the performance and hemocompatibility of the P-ModELAS 
and its long-term effect on the cardiopulmonary system. 
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6.0 Chronic In Vivo Performance of the Pediatric ModELAS 
Platelet activation studies were conducted by Sang-Ho Ye, Ph.D.  
6.1 Introduction 
ECMO and mechanical ventilation are used to bridge respiratory failure patients to lung 
transplant. Pediatric lung transplant recipients, however typically wait 1 – 6 months for a transplant 
after being listed.63 During this waiting period, ECMO patients who participate in physical therapy, 
including ambulating within the ICU, have improved post-transplant outcomes.72,75 Cannulation 
in these patients should therefore accommodate long-term, ambulatory support. 
Arterio-venous and veno-venous ECMO cannulation strategies have both been employed 
in pediatric patients. The use of dual lumen cannulas is becoming popular in the adult ECMO 
population and is generally considered less invasive as it requires cannulation of a single vein. In 
pediatric ECMO patients, however, a central cannulation is often preferred over dual lumen 
cannulation at the neck.80 This preference is due to patient cooperation, blood recirculation, and 
limited availability of appropriate dual lumen cannula sizes. Based on pediatric ECMO cases 
reported to the ELSO registry between 1998 and 2011, there is not a significant difference in 
survival to discharge between patients receiving multisite VV-cannulation and single site, dual 
lumen cannulation.138 
To accommodate long-term support of potentially ambulatory patients, the P-ModELAS 
has been designed to be connected to the vasculature via the RA and PA. This cannulation strategy 
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is surgically more invasive than single site DLC cannulation, however it best meets the needs for 
ambulatory, pediatric ECMO. Previous work has demonstrated that the P-ModELAS meets design 
specifications in vitro,84 and has shown that the device can be connected to sheep for up to 6 hours 
without complication.121 The next step in the advancement of the P-ModELAS is to develop 
methods for recovering the animal post-thoracotomy. The objective of this series of 7-day studies 
was to establish post-operative anticoagulation management methods for animals following P-
ModELAS implantation. Study success criteria was based on cessation of the chest tube output, 
animal survival and device free of thrombus. These 7-day studies represent the next step towards 
30-day in vivo evaluation of the P-ModELAS. 
6.2 Methods 
6.2.1 7-Day In Vivo Testing 
The P-ModELAS was evaluated for 7 days in juvenile Dorper or Hampshire sheep (n=3, 
23.8 – 26.5 kg). These studies were completed at the McGowan Institute’s Center for Preclinical 
Studies under a protocol approved by the University of Pittsburgh’s Institutional Animal Care and 
Use Committee.  
Anesthesia was induced via a subcutaneous injection of atropine (0.25 mg/kg) followed by 
an intravenous infusion of ketamine (4.0 mg/kg). Inhaled isoflurane was used to maintain 
anesthesia during the surgical procedure. A venous line was placed in the left jugular vein and an 
arterial line was placed in the left carotid artery via a surgical cut down. These lines were sutured 
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to the vessel and tunneled underneath the skin for additional securement. A baseline ACT blood 
sample was drawn from the arterial line prior to any heparin administration. 
A right thoracotomy allowed access to the RA and PA. Prior to cannula placement a 150 
IU/kg heparin bolus was given to increase the ACT to at least 300 seconds (ACT-II, Medtronic, 
Minneapolis, MN). When necessary additional 1000 IU heparin boluses were administered to 
increase the ACT to 300 s. A 22 Fr venous cannula (Medtronic DLP Single Stage (#69322)) was 
sutured into the RA and an 18 Fr arterial cannula (Medtronic EOPA (#77518)) was sutured into 
the PA. The cannulas were tunneled underneath the skin and connected to a primed device (1 
IU/mL heparin in normal saline) and extracorporeal blood flow initiated. A chest tube was placed 
in the thoracic cavity and connected to a Pleur-Evac system.  
Extracorporeal blood flow was started at 2 – 2.5 L/min. The pure oxygen sweep gas flow 
rate was initially set to 4 L/min. The chest was closed and the animals were recovered in the ICU. 
The animals remained in a stanchion for the duration of the study. The P-ModELAS was placed 
in a modified backpack, and secured to the left side of the animal via backpack straps. Tension 
cables were used to relieve the animal of a portion of the device weight. Nicardipine (0.5 
mcg/kg/min initial rate) was titrated to maintain a MAP of 85 – 90 mmHg, an analgesic (1 mg/kg 
flunixin meglumine as needed) and an antibiotic (0.25 mg/kg cefazolin daily) were also 
administered. 
Blood was drawn for pfHb, platelet activation, complete blood count and a blood chemistry 
panel. Baseline blood samples were drawn on pre-operative days 5 and 1. Post-operative blood 
work was scheduled for 4 post-operative days. The blood sampling schedule was altered if the 
hematocrit was below 18% to maintain animal welfare. Methods for pfHb and platelet activation 
measurements have been previously described in detail.69,123 Complete blood counts and blood 
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chemistry panels were completed by an external laboratory (IDEXX Laboratories, Inc, Westbrook, 
ME). Chest tube output was measured hourly. Blood flow rate, motor torque, device RPM and 
animal hemodynamics (heart rate, MAP, CVP) were recorded hourly. Device inlet and outlet blood 
gas samples were taken to measure the oxygenation rate of the device daily unless low hematocrit 
required altering the schedule. The inlet blood gas parameters were used as the input parameters 
to a previously developed and validated mass transfer model to attain a predicted oxygenation 
rates.84 
6.2.1.1 Post-Operative Anticoagulation 
During Trial 1, the post-operative heparin infusion was immediately started and titrated to 
achieve an ACT target of 1.5 – 2 times the baseline ACT. The ACT was maintained via a 
continuous heparin infusion through the animal’s venous line. The ACT was measured every 4 
hours. During Trial 2, heparin was not administered post-operatively until the chest tube output 
rate had plateaued and transitioned to serous fluid. The continuous heparin infusion was then 
initiated at a rate of 15 IU/kg/hr and increased at this rate until the ACT reached 1.5 – 2 times the 
baseline value. During Trial 3, an initial post-operative continuous heparin infusion of 25 IU/kg/hr 
was started and held at this rate until the chest tube output stabilized and transitioned to serous 
fluid. The heparin infusion rate was then increased step-wise until the 1.5 – 2 times baseline ACT 
target was achieved. During Trials 2 and 3 ACT was not measured until the heparin infusion was 
started in Trial 2, or increased in Trial 3, to prevent anemia due to blood sampling. ACT was then 
measured every 4 – 6 hours unless low HCT required altering the schedule.  
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6.2.2 Statistical Analysis 
Data is represented as the mean ± standard deviation. The reported mean represents the 
average of each trial’s averaged data during the specified time range. Data was binned into groups 
of pre- and post-operative days in order for there to be a sufficient number of measurements to 
permit statistical analysis. This was required due to skipped or postponed blood sampling due to 
low hematocrit and the early termination of Trial 1. 
Motor torque, extracorporeal blood flow rate, and the oxygenation rate had an unequal 
number of samples within each POD grouping due to the early termination of Trial 1. As a result 
these parameters were statistically analyzed using a mixed linear model ANOVA and utilized the 
restricted maximum likelihood estimation method.125 Parameters which violated the assumption 
of normality based on the Kolmogorov-Smirnov Test for Normality were normalized prior to 
statistical evaluation.126 All other parameters were evaluated using a repeated measures ANOVA 
with Bonferroni post-hoc analysis. Statistical analysis was completed using SPSS software (IBM, 
Armonk, NY). Differences were considered significant at p < 0.05. 
6.3 Results 
All animals were successfully recovered and stood post-implant. Trials 2 and 3 were 
electively terminated at the scheduled end of study on POD 7. Trial 1 required a blood transfusion 
on POD 3 due to anemia and early termination on POD 4 due to dyspnea and pain non-responsive 
to analgesia. Trial 3 required a device exchange within the first 3 hours of the study.  
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Table 7 provides the daily averages of animal hemodynamics and device parameters. The 
P-ModELAS was operated at impeller speeds between 1328 and 1508 RPM. Blood flow rate 
ranged from 1.9 ± 0.6 L/min to 2.4 L/min. Animal hemodynamics remained stable throughout the 
study. The oxygenation rate ranged from 95.5 mL/min to 105.3 mL/min, and did not significantly 
change over the course of the study (p = 0.255) (Figure 15). Blood exited the device at oxygen 
saturations ranging from 68.1% to 100% and inlet saturations ranged from 13.9% to 71.9%. The 
in vivo data was within 10% of the oxygenation rate predicted by the mass transfer model. 
 
Table 7 Device and Hemodynamic Parameters 




    
MAP [mmHg] 
 
81 ± 3 80 ± 1 83 ± 6 80 
CVPa [mmHg] 
 
6 6 8 8 
Heart Rate [BPM] 
 
128 ± 19 147 ± 15 167 ± 22 165 
Blood Flow Rate [L/min] 
 
2 ± 0 2 ± 0 2 ± 1 2 
Motor Torque [mN-m]  15 ± 4 13 ± 3 13 ± 3 14 
Device Speed [RPM] 
 
1499 ± 243 1379 ± 179 1328 ± 187 1328 




Figure 15 In Vivo Gas Transfer 
(A) Average experimental and predicted oxygenation rate over the course of the study.  (B) Device inlet and 
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Post-operative average in vivo hemolysis was below 20 mg/dL (Table 8). There was no 
statistical increase from baseline (POD 0) hemolysis (p = 0.052). CD62P positive platelets 
remained below 22.6%, and those stimulated with platelet activating factor (PAF) showed 
increased activity of at least 74%. Platelet concentration was analyzed microscopically and ranged 
from 295 – 1048 K/µL. Liver (ALT and AST) and kidney (creatinine and BUN) biomarkers 
remained within the normal range for sheep and did not statistically change over the course of the 
study. The HFM bundle was free of thrombus after Trials 1 & 3, and contained a thrombus 
occluding ~30% of the bundle in Trial 2. Small thrombi were adhered to the bottom pivot of the 
impeller in all trials. All other aspects of the devices were free of thrombus.  
 
Table 8 Hemodynamic and End Organ Parameters 
Parameter   Pre-Operative   POD 0 - 3
a   POD 4 - 7b 
                          
Hematocrit [%]   36 ± 2   24 ± 3*   21 ± 7 
Platelet Count [K/µL]   711 ± 188   376 ± 22   845 ± 655 
CD62-P [%]   5.2 ± 2.6   5.4 ± 1.9   17.2 ± 7.8 
PAF Activated [%]   88.0 ± 2.9   74.5 ± 7.7   88.3 ± 3.0 
WBC [k/µL]   8.2 ± 1.6   6.2 ± 2.3   16.9 ± 3.1 
PfHb [mg/dL]   26.2 ± 8.0   13.9 ± 0.7   15.6 ± 3.2 
                          
ALT [U/L]   9 ± 7   8 ± 6   9 ± 9 
AST [U/L]   88 ± 23   97 ± 35   77 ± 13 
Creatine Kinase [U/L]   146 ± 46   1324 ± 625   140 ± 71 
Blood Urea Nitrogen [mg/dL]   11 ± 2   11 ± 1   24 ± 23 
Creatinine [mg/dL]   1 ± 0   1 ± 0   1 ± 1 





The average total chest tube output was 1.1 ± 0.1 L. The chest tube output transitioned 
from blood to serous fluid on POD 1, and the output rate plateaued on POD 3 during all trials 
(Figure 16). A heparin pump malfunction on POD 1 of Trial 1 resulted in the ACT increasing to 
greater than 4 times the baseline value. Subsequently, 595 mL of fluid, primarily blood, was 
drained from the chest tube and an ACT of 1.5 times the baseline ACT was targeted for the 
remainder of the Trial 1 to prevent further bleeding. Trial 1 output transitioned back to serous fluid 
again on POD 3. During Trial 2, heparin was started 28 hours post-operatively and was within the 
1.5 – 2 times baseline ACT range on POD 4. Increases in the heparin rate of Trial 3 were made 
starting on POD 3 and the ACT reached the targeted 1.5 – 2 times baseline ACT range on POD 5.   
During the necropsy of Trial 1, approximately 1200 mL of blood was removed from the 
thoracic cavity. No source of the bleeding was identified. Adhesions were noted between the heart 
and sternal area and between the right lung and the heart. The right lung positioning was more 
dorsal than normal and showed diffuse atelectasis. Histopathological analysis of the lungs 
contained moderate to severe areas of hemorrhage, fibrin deposition and interstitial pneumonia. 
Both kidneys contained small infarcts and both medulla areas were hemorrhagic. Atelectasis of 
the right lung was present in Trials 2 and 3 and can be attributed to surgical manipulation. Upon 
the necropsy of Trial 3, widespread fungal growth was identified throughout the thoracic cavity 
and 150 mL of sero-hemorrhagic and purulent fluid was removed from the chest. This was likely 




Figure 16 Cumulative Chest Output Over Course of Study 
Cumulative chest tube ouput for Trial 1 (top left), Trial 2 (top right) and Trial 3 (bottom). Initial output measurement was taken post-operatively in the 
ICU after the animal stood 
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Mechanical ventilation and current ECMO devices used to support pediatric lung failure 
patients restrict patient mobility. Evidence demonstrating improved post-transplant outcomes for 
patients whom participated in active physical rehabilitation, including ambulation, is 
increasing.72,75,139 The P-ModELAS is being developed to address the need for an ECMO device 
which allows patient ambulation. In this study, the P-ModELAS was evaluated in awake sheep for 
7 days with the primary objective to develop a suitable post-operative anticoagulation strategy. All 
animals survived the surgery, and two of the animals survived the entire study duration. The post-
operative anticoagulation strategy was refined through this series of studies.  
The Pediatric ModELAS was generally well tolerated by the animals. There was not a 
substantial change in animal hemodynamics or platelet function over time (p > 0.05). Post-
operative plasma free hemoglobin did not exceed 20 mg/dL and was well below the threshold of 
40 – 50 mg/dL.114,127,128 Elevated pre-operative pfHb measurements are the result of samples being 
drawn via a venous puncture. Trial 2 required a device exchange within the first 3 post-operative 
hours due to high bundle resistance and decreasing extracorporeal blood flow rate. Air was 
observed in the bundle inlet plenum when extracorporeal blood flow was initiated in the operating 
room. Air in this location at the initiation of extracorporeal support is a result of incomplete 
priming of the pumping compartment or the inflow cannula and tubing. This was an isolated 
incident and additional measures were taken during Trial 3 to ensure the circuit was completely 
de-aired. The small thrombi which formed at the bottom pivot-bearing were not associated with 
increases in motor torque or pfHb. Subsequent ModELAS impeller design iterations have 
incorporated washout holes to increase blood velocity at the pivot-bearing, and exchanged the 
ceramic pivot for a smoother surfaced zirconium pivot. Both of these design changes were 
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implemented in the ECCO2R 7-day studies, reported in Chapter 4, and bottom pivot-bearing 
thrombus did not normally occur. Future P-ModELAS in vivo studies will include these design 
modifications and similar improvements are expected since the ECCO2R and P-ModELAS utilize 
identical pumps operated at similar RPM.  
The average in vivo oxygenation rate was 95.1 ± 3.7 mL/min. The model predicted 
oxygenation rates within 10% of those measured during the in vivo experiments. Thus, changes in 
the measured oxygenation rate were likely caused by changes in the hemoglobin concentration and 
O2 saturation of the inlet blood. The comparison to the model aids in distinguishing between 
lowered gas transfer rates due to bundle thrombus and an expected decrease in vO2 resulting from 
non-standard venous inlet blood conditions. The major caveat though is in a perfusion limited 
regime, where the blood exits the device fully saturated, early or small intra-bundle thrombi would 
not be detectable based solely on vO2. In future in vivo studies, the vCO2 will also be measured to 
evaluate the patency of the HFM bundle. Carbon dioxide removal rate is the most sensitive 
indicator of early bundle thrombus111 and work described in Chapter 3 of this thesis has provided 
a means to account for changes in vCO2 due to changes in hematocrit. 
The surgical invasiveness of the thoracotomy increases the risk of post-operative bleeding 
compared to the DLC cannulation strategy employed with the other ModELAS configurations. 
The anticoagulation strategy of the P-ModELAS must balance the need for coagulation at the 
surgical incisions with the extracorporeal circuit’s anticoagulation requirement. All of the trials 
had approximately 1 L of chest tube output over the course of the study and output plateaued by 
POD 3. The first trial utilized a relatively aggressive anticoagulation strategy immediately post-
operatively. This study was prematurely terminated due to dyspnea, likely resulting from the 
hemothorax. Subsequent studies used low or minimal heparin post-operatively until the chest tube 
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output rate stabilized and did not require early termination. The P-ModELAS tolerated this 
timeframe of low heparin well as demonstrated by devices generally free of thrombus. The 
explanted device from Trial 2 did have thrombus within the bundle, however bundle resistance did 
not increase and gas transfer did not decrease over the course of the study. Thus, it is likely that 
thrombus formed as the device was being removed from the animal post-study. In Trial 3, the ACT 
was increased to greater than 300 s prior to removing the device to prevent thrombus formation as 
the device is being removed. The addition of vCO2 measurements during future in vivo studies 
will also improve the identification of intra-device thrombus during the study.  
Other research groups have faced similar preclinical challenges when cannulating via a 
thoracotomy. Wang and Zwischenberger secure the cannulas into the RA and PA then 12 – 24 hrs 
later splice in the OxyRVAD device and anticoagulation restarted. This waiting period was done 
to allow the reversal of systemic anticoagulation and the chest incisions to begin to heal. One of 
the five OxyRVAD animals required early termination due to bleeding complicatoins.140 Although 
the nature of animal studies sometimes require methodologies that may not be employed clinically 
a respiratory device that requires a 12 – 24 hour waiting period also delays respiratory support to 
the patient. The methodology used during these 7-day P-ModELAS studies is more challenging 
from a device perspective, however it is also a more clinically realistic approach.  
The low number of trials and the use of different anticoagulation protocols during each 
trial is a limitation of these studies. Only 2 trials survived the entirety of the study and all three 
trials required postponed or skipped blood sampling. Specific conclusions regarding the 
hemocompatibility and performance of the device therefore should be made cautiously. Repeated 
trials using the recovery methodology of Trial 3 were not completed due to results from concurrent 
adult ModELAS 30-day studies and the platform nature of the ModELAS. An improved impeller 
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design has been implemented into the adult respiratory support ModELAS to mitigate thrombus 
formation at the bottom pivot-bearing and is currently being evaluated in 30-day adult ModELAS 
in vivo studies. Since all three ModELAS respiratory assist applications utilize an identical pump, 
improvements made to the adult device can be applied to the pediatric application as well. 
Additionally, from our experience transitioning from 5-day to 30-day adult in vivo studies, there 
will likely be unforeseen challenges during 30-day P-ModELAS studies. Thus, the decision was 
made to forego additional 7-day testing and transition to 30-day P-ModELAS studies once the 
successful 30-day adult ModELAS studies have been completed. 
6.5 Conclusion 
The P- ModELAS is a compact, integrated artificial pump-lung, and was connected to 
sheep for 7-days (n=3). One study required early termination, and one study required a device 
exchange within the first 3 hours of the study. The central goal of these studies was to develop the 
anticoagulation protocol during the first 48 – 72 post-operative hours. Future long-term studies 
will have an initial post-operative heparin infusion of 25 IU/kg/hr and it will be increased at this 
rate once the chest tube output rate has plateaued, as was done in Trial 3. Upcoming chronic 30-
day ovine studies will build upon these 7-day studies and further evaluate performance and 
hemocompatibility of the P-ModELAS.  
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7.0 In Vitro Thrombus Formation 
Platelet activation measurements were conducted by Sang-Ho Ye, PhD and CFD analysis 
was completed by Greg Burgreen, PhD.  
7.1 Introduction 
Thrombus formation within an artificial lung continues to be an important clinical issue. 
One report attributes 20% of ECMO device exchanges to acute or suspected thrombi.130 To reduce 
intradevice thrombus formation, researchers have focused primarily on improving the 
biocompatibility of the blood contacting surface and eliminating blood stagnation zones. 
Improvements to material biocompatibility range from thromboresistant surface coatings to 
reducing the surface roughness of blood contacting surfaces.28,141 Stagnation zones can be 
challenging to identify and eliminate. Extracorporeal devices such as the Hemolung RAS and the 
TandemHeart ventricular assist device utilize a continuous saline flush to clear blood from the 
pivot and pump thereby preventing thrombus formation.142,143 A saline flush however is not 
suitable for the long-term device goals of the ModELAS due to the required additional port and 
infection risk. Alternatively, washout holes have been incorporated into impellers to circumvent 
the need for a saline flush by providing a flow path to drive fluid from the pivot-bearing back into 
the main blood flow pathway.144,145   
The 30-day in vivo evaluation of the adult ModELAS full respiratory device resulted in all 
(n = 4) of the first-generation impeller devices containing significant thrombus at the bottom pivot-
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bearing. This thrombus resulted in elevated plasma free hemoglobin, elevated motor torque and in 
one instance motor failure.146 A second-generation impeller was designed with zirconium pivots 
and washout holes in an effort to improve thrombogenicity and washing at the bottom pivot-
bearing. The zirconium pivot surface is an order of magnitude smoother than the ceramic pivots 
used in the first-generation impeller.  
The challenge however is evaluating and comparing the thrombogenicity of these design 
modifications within the ModELAS. The gold standard comparison is in vivo comparisons of the 
modifications however, this approach is cost prohibitive. Recently, in an effort to mitigate cost, 
multiple groups have published methods to evaluate thrombus formation in vitro.147,148 These 
methods, however, have typically been limited to evaluating thrombus formation via simple flow 
through a catheter or over a biomaterial. The ability to compare thrombogenicity of design changes 
in full devices in vitro would enable more rapid and efficient evaluation of design modifications. 
In this chapter, methods are developed to evaluate the effect of pivot material surface 
roughness and impeller washout holes on the thrombogenicity of the ModELAS impeller. 
Thrombogenicity comparisons were based upon the thrombus dry weight and surface area at the 
bottom pivot. Platelet activation studies evaluated the effect of blood flow through the washout 
holes. The results of this work aim to not only evaluate the thrombogenicity of these design 
changes but also develop an in vitro testbed capable of examining the thrombogenicity of future 
ModELAS design iterations.  
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7.2 Methods 
7.2.1 Impeller Description 
Vertical cross sections of the baseline (no washout hole) impeller and the washout hole 
impeller are shown in Figure 17. The impeller vanes, pivot locations and the coupling magnet 
locations are identical in both impellers. The washout hole impeller contains 6 equidistant holes 
leading from the bottom pivot to one of the six impeller vanes. The holes are 0.8 mm in diameter 
and angled at 24°. The angled washout holes draw blood from underneath the impeller back into 
the main blood flow channels of the impeller and were optimized using computational fluid 
dynamics. The angled design maintains the hydrodynamic and magnetic forces on the impeller.144 
The sole difference between the ceramic and zironcium pivot impellers is the pivot material. 
 
 
Figure 17 Cross Section of Impeller 
Cross sections of the no washout hole impeller (left) and the washout hole impeller (right). Arrows indicate 
blood flow through the washout holes. 
7.2.2 In Vitro Circuit 
Ovine blood was purchased from Lampire Biologics (Pipersville, PA) and anticoagulated 
with acid citrated dextrose formula A. The blood was completely recalcified (3 g/L CaCl2) and 
heparinized (3.5 U/mL) and treated with L-glutamine (2 mmol/L) and gentamicin (2.5 mL/L) to 
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preserve red blood cell integrity and prevent infection.148 The heparin concentration was 
determined via a previously described static pretest.147 Each test loop consisted of a 600-mL 
compliant reservoir submerged in a 37 °C water bath, and a modified ECCO2R ModELAS device. 
Resistance of the HFM bundle and 15.5 Fr ALung dual lumen catheter were predicted by Blake-
Kozey equation149 and Hagan-Poiseuille equation, respectively. These resistances were simulated 
in the in vitro circuit by a 1/8 inch blood flow path where the HFM bundle normally resides and 
5/16 inch tubing within the circuit. The cannula and fiber bundle were removed from the circuit to 
prevent thrombus formation in either of these locations. Thrombus does not consistently form in 
either the tubing or in the fiber bundle based on data from our in vivo studies with this device.  
The control impeller device and the test impeller device were run in parallel with blood 
from the same animal (indicated by blood group 1 and blood group 2) to eliminate any influence 
hematologic variability between animals may have on the experiment. The device RPM was set to 
achieve a blood flow rate of 500 mL/min, and was not adjusted. Blood flow rate was recorded 
every 30 minutes. Activated clotting time (ACT), pfHb and hemoglobin concentration were 
measured every 1.5 hrs. At the completion of the study each device was disconnected from the 
circuit, passively flushed with phosphate buffered saline and disassembled. Each blood contacting 
surface of the device was photographed with a ruler for scale. The top and bottom of the impeller 
were identically photographed after each repetition of the experiment.  
7.2.3 Image Processing and Heat Map Generation 
The images of the impeller were imported into ImageJ. The scale of the image was set 
based on the ruler within the photograph and the images were cropped to a square the width of the 
impeller. If necessary, the image was scaled to exactly 3424 x 3424 pixels (1023 pixels/inch). The 
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color threshold was adjusted to a hue of 16 to 253, a brightness of 1 to 14 and passed saturations 
between 83 and 255. The thrombi were subsequently selected using the ImageJ wand tool. The 
area of the thrombi was then calculated via the ImageJ measure function. ImageJ software was 
then used to create a mask of the thrombi selection. The masks of each repeated trial were then 
layered into a single stacked image and exported to MATLAB. 
The MATLAB program analyzed each layer of the stacked image on a pixel-by-pixel basis 
to determine the number of layers which contained thrombus at each pixel. Identical pixel locations 
on each layer were then averaged, the layered average. Thus, if 3 of the 5 trials contained thrombus 
within a certain pixel the layered average would be 0.6. The impeller image was then divided into 
concentric bins each spaced 15 pixels (equivalent to 0.015 inch) radially apart. The color of each 
bin represents the average of all the layered averages within that bin. The pivot was excluded from 
this analysis.  
 
7.2.4 Platelet Activation 
Platelet activation was evaluated in zirconium pivot impellers with and without washout 
holes. The recirculation loop was identical to the previously described loop. The circuits were 
primed with a 1% bovine serum albumin (BSA) solution and the solution was recirculated for at 
least 20 minutes. Excess BSA solution was drained from the circuit and 125 mL of ovine blood 
(ACD-A 1:9) from a donor sheep filled the circuit. Ovine blood was purchased either from Lampire 
Biologics and used 24 hours after being drawn (referred to as 24-hour old blood), or from a local 
sheep farm and used within 3 hours of being drawn (referred to as fresh blood). The RPM of the 
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device was increased until the blood flow rate was 0.5 L/min. Blood was allowed to recirculate for 
1 hour. 
A 3-mL blood sample was drawn from the blood donor bag and placed in an S-Monovette 
tube (SARSTEDT AG & Co, Germany) for baseline PAF activation measurements. Blood samples 
were drawn from each of the circuits and placed in an S-Monovette tube at 0 min, 15 min, 30 min 
and 60 min to measure CD62P expression. At the 1-hour time point an additional 3 mL sample 
was drawn from each loop to measure end of study PAF activation. PAF stimulated samples were 
used to evaluate the functionality of the circulating platelets. Details of the flow cytometry methods 
used to measure CD62P expression have been previously described.123,124 
7.2.5 Statistical Analysis 
Data are reported as the mean ± standard deviation. Statistical analysis was completed in 
SPSS (IBM, Armonk, NY). A student t-test was conducted to evaluate statistical significance of 
thrombi mass and surface area. A repeated measures ANOVA was completed to compare and 
determine the statistical significance of the platelet activation data. Comparisons were significant 
at p < 0.05. 
7.3 Results 
The thrombus mass and surface area formed on the ceramic-no washout hole impeller was 
greater than that formed on the zirconium-no washout hole impeller (p = 0.03 and p = 0.02, 
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respectively) (Table 9). The addition of washout holes to a zirconium pivot impeller did not affect 
the mass or surface area of thrombus formed (p = 0.28 and p = 0.34, respectively) (Table 9). 
Heat maps of the bottom face of the impeller were generated to depict the frequency of 
thrombus formation at different concentric regions (Figure 18). Thrombus primarily occurred at 
the pivot and with decreasing frequency as one moves radially outward toward the edge of the 
impeller for all pivot and washout hole combinations. The ceramic pivot resulted in thrombus 
formation within 0.028 inches of the pivot in 100% of the trials. The maximum frequency of 
thrombus formation for all zirconium pivot impellers without washout holes was 40% and with 
washout holes 32%. These maximums occurred within 0.028 inches of the pivot. The zirconium 
pivot-washout hole impeller had thrombus that extended to a maximum radial distance of 0.059 
inches. 
 
Table 9 Thrombus Mass and Surface Area 
 Blood Group 1  Blood Group 2 
 
Ceramic 
Pivot   
Zirconium 
Pivot   
Zirconium 






 No Washout 
Holes+ 
 No Washout 
Holes‡   
Washout Holes‡ 
                 
Thrombus 
Mass [mg] 
8.9 ± 6.2* 
 
2.6 ± 1.9* 
  
0.9 ± 1.6 
 
2.7 ± 4.6     
 




1.72 ± 1.1† 
 
0.4 ± 0.3† 
  
0.2 ± 0.3 
 
0.4 ± 0.6 
      
*,† Statistically significant (p < 0.05) compared to other pivot material; 





Figure 18 Heat Map Indicating Thrombus Location at Bottom Pivot 
Ceramic pivot without washout hole impeller (top left), zirconium pivot without washout holes (top right), 
zirconium pivot without washout holes (bottom left), and zirconium with washout holes (bottom right). White 




Figure 19 CD62P Expression -- 24 Hour Old Ovine Blood 
24-hour old ovine blood initially anticoagulated with ACD-A, then recalcified and heparinized just prior to 
being placed in the circuit. Baseline CD62P expression of PAF activated platelets was measured prior to 
blood being added to the circuit. (n=2) 
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Figure 20 CD62P -- Fresh Ovine Blood 
Fresh (less than 4 hour post-draw) ovine blood initially anticoagulated with ACD-A, then recalcified and 
heparinized just prior to being placed in the circuit. Baseline CD62P expression of PAF activated platelets 
was measured prior to blood being added to the circuit. (n=2) 
 
 





























N o  W ash o u t H o les W a sh o u t H o les
B ase lin e  P A F  A ctiv a ted
96 
 
Figure 21 CD62P Expression -- Fresh Ovine Blood 
Fresh (less than 4 hour post-draw) ovine blood anticoagulated with ACD-A and evaluated without 
recalcification. Baseline CD62P expression of PAF activated platelets was measured prior to blood being 
added to the circuit. End of study (EOS) PAF activated platelet samples were drawn from the circuit at the 
end of study. (n=3) 
 
Figures 19 - 21 provides the percentage of platelets expressing CD62P, an indicator of 
platelet activation. Blood used 24 hours after collection (ACD-A added at collection, complete 
recalcification with CaCl2 and heparin added just prior to start of study) showed low baseline 
CD62P expression (46.8%) when a PAF was added (Figure 19). Ovine blood collected and used 
within 4 hours (ACD-A added at collection, complete recalcification with CaCl2 and heparin added 
just prior to start of study) showed acceptable PAF activated CD62P expression (68.5%) however 
over 50% of the platelets had become activated within the first 30 minutes of the study (Figure 
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20). Ovine blood collected and used within 4 hours (ACD-A added at collection, no recalcification) 
had acceptable baseline PAF activated CD62P expression (71.9%) (Figure 21). CD62P expression 
was not substantially different between the washout hole device and the no washout hole device 
(p = 0.574). Platelet activation did not increase over the course of the study (p = 0.155). 
7.4 Discussion 
Thrombus formation within the first generation ModELAS pump has been a consistent 
issue in vivo and resulted in increased hemolysis and motor torque. The second generation 
ModELAS pump includes zirconium pivots, which are smoother surfaced, and washout holes 
within the impeller in order to prevent this thrombus formation. In vitro hemolysis testing and 
CFD analysis has previously been the extent of testing done prior to in vivo evaluation. This 
however, can be costly. This chapter discusses the initial development and results of an in vitro 
protocol to evaluate the thrombogenicity of ModELAS impeller designs. Multiple sources of ovine 
blood, and anticoagulation regimes were evaluated for platelet activation and thrombus formation. 
This study demonstrated significantly less thrombus formation on the zirconium pivots, but no 
significant effect of the washout holes. The washout holes, however did not affect platelet 
activation. 
Full device, in vitro thrombogenicity and platelet activation testing is challenging. The 
largest challenge is properly attaining and anticoagulating the donor blood in order to maintain 
platelet functionality ex vivo. The present study evaluated 24-hour old and same day ovine blood 
as well as complete recalcification with CaCl2 and no recalcification. The same day ovine blood 
consistently showed baseline PAF activation similar to that seen during in vivo experiments 
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(Chapter 4) whereas blood stored for 24 hours show diminished platelet functionality. The 
literature also recommends that blood is used within 4 hours of being drawn for thrombogenicity 
testing.150 The drawback to fresh ovine blood is the availability of donor sheep, the cost of 
maintaining in-house donor animals, and the volume and frequency of blood draws. Despite the 
availability of fresh ovine blood for the present work, restrictions to the volume and frequency of 
blood draws resulted in the thrombus formation and platelet activation studies needing to be 
completed separately. In the present study, only 250 mL of fresh ovine blood was able to be 
procured per day which equates to 125 mL per recirculation circuit. The total sample volume 
required for the platelet activation measurements (15 mL) depleted the blood reservoir and the 
blood was unable to be recirculated after 1 hour. Thrombus formation circuits required additional 
volume to permit blood sampling and maintain adequate reservoir volume for recirculation, 
therefore the experiments were separated and 24-hr old blood was used in the thrombus formation 
experiments. Jamiolkowski, et al. have shown 24-hr old blood is viable for thrombus formation 
testing.147 
A two-fold approach, zirconium pivots and addition of washout holes, was taken in order 
to decrease the pivot surface roughness and increase fluid washing at the bottom pivot, 
respectively. Linnewaber et al. demonstrated a 38.5% decrease in platelet adhesion when whole 
blood was exposed to surfaces with a surface roughness of 0.05 μm compared to 0.2 – 0.4 μm.141 
Increased surface roughness of catheters has also been correlated to an increase in thromboembolic 
complications in human and animal models.151,152 In the present study a change from a ceramic to 
zirconium pivot (representing a 98.5% decrease in surface roughness) substantially decreased the 
surface area and mass of the thrombus formed at the bottom pivot-bearing.  
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The experimental design, however does not allow one to differentiate the possibility of 
zirconium being inherently more anti-thrombotic than ceramic, independent of surface roughness. 
Previous studies, however, have evaluated surface roughness as an independent factor influencing 
thrombus formation. Catheters extruded from a single batch of polyvinylchloride resin at varying 
temperatures (temperature variations result in changes to the surface roughness) showed that 
greater surface roughness resulted in greater thrombus formation and concluded this may be due 
to better adhesion of the thrombus to the biomaterial.153 Tsunoda, et al. also showed that cellulose 
HFM with rougher surfaces had higher platelet adhesion and concluded that surface roughness 
may dictate flow conditions at the surface which in turn affects thrombogenicity.154 Both of these 
explanations indicate that greater surface roughness, independent of the material, results in 
increased thrombus formation. Thus, regardless of the inherent thrombogenicity of ceramic and 
zirconium, the smoother surface of the zirconium pivot is likely a contributing factor to decreased 
thrombus formation. 
Blood flow stasis is one contributor to thrombosis based on Virchow’s triad, thus washout 
holes were added to the impeller design to drive blood from underneath the impeller back into the 
main, high flow, impeller vanes. The addition of washout holes to the zirconium pivot impeller, 
however, did not further improve thrombus formation at the bottom pivot. One reason for this may 
be ingestion of upstream thrombus by the pump. Small thrombi, which may form at the pre-pump 
tubing connectors or within the reservoir bag, can dislodge and be ingested by the pump. Due to 
the size of the washout holes, it is likely that any thrombi drawn into the washout holes will occlude 
the hole. Once blood flow through the washout holes is occluded, the washout hole impeller 
essentially becomes the no washout hole impeller as blood no longer has a pathway from the 
bottom surface of the impeller back into the main blood flow channels. Although thrombus 
100 
originating with the blood reservoir in not a challenge in the ModELAS in vivo setting, thrombus 
formation at tubing connectors is a well-known clinical challenge.155 Thus further washout hole 
design improvements are required to improve the ability of the washout holes to handle ingested 
thrombus. 
One potential complication of the washout holes is shear induced platelet activation 
resulting from blood flow through the small diameter washout holes. Exposure to the 
supraphysiological shear stresses present within blood pumps can result in irreversible platelet 
activation and aggregation without exogenous agonists.156 This chronic platelet activation can in 
turn increase the risk of adverse, thromboembolic complications.157 Typical human arteries have 
a shear stress of 1.4 – 6.1 Pa,158–160 and several studies have demonstrated that shear stresses of 10 
– 50 Pa are sufficient to cause platelet activation.161,162 CFD analysis predicted typical shear 
stresses within the washout holes to be 13 – 50 Pa, and thus sufficient for platelet activation. The 
present in vitro data, however, did not show a statistical increase in platelet activation due to the 
washout holes. This is probably due to noise, or activation, from the rest of the system. Designing 
a test fixture to isolate blood flow through the washout holes would allow one to determine whether 
or not the washout holes activate platelets. However, this determination would be binary, and does 
not provide insight as to the potential clinical relevance of the platelet activation. Interestingly, 30-
day in vivo data utilizing the zirconium pivot-washout hole impeller did not show a clinically 
relevant increase in platelet activation (CD62P expression less than 10%).163 Thus the washout 
holes may in fact be activating platelets, however the platelet activation contribution from the 
washout is not substantial in comparison to the platelet activation resulting from blood flow 
through the pump. Ultimately, a design which creates clinically relevant platelet activation in vivo 
101 
needs to be evaluated using the in vitro protocol presented within this chapter to determine the 
sensitivity of this in vitro activation assay.  
Although limited comparisons to in vivo studies show general agreement with these in vitro 
results there are several limitations and aspects of this study which may be improved upon. The 
implementation of additional blood inclusion criteria, beyond platelet activation, would likely 
further reduce variability between repeated trials. For example, one group used thrombus surface 
coverage of PTFE and Latex material incorporated into the circuit to ensure consistent 
coagulability of the donor blood.147 The sensitivity of these in vitro thrombogenicity studies is also 
unclear based upon the current results. The test is sensitive enough to differentiate between the 
surface roughness of different materials (ceramic vs zirconium), however it may not have the 
sensitivity to elucidate subtle difference, such as between washout holes and no washout holes. At 
present, there is not ModELAS in vivo data corresponding to the zirconium-no washout hole 
condition to confirm the in vitro no washout hole results. However, in vivo data does not indicate 
any adverse effects of including the washout holes.163 
There is no accepted standard protocol for in vitro thrombogenicity testing. Multiple groups 
have evaluated in vitro thrombogenicity however there is significant methodological variability 
amongst groups. Literature has reported temperature ranges from room temperature to 37 °C, study 
durations have been reported 15 minutes164 to 48 hours148 and blood sourced from a fresh donor165 
to blood that is 24 hr post draw.147 These studies however have been primarily limited to 
correlating thrombogenicity to the quantity of adhered platelets. The FDA is also actively pursuing 
methods to evaluate in vitro medical device thrombogenicity, however the testing has been limited 
to flow over biomaterial samples.147,166 The creation of a standardized protocol would decrease 
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variability between research groups and improve the predictive power of an in vitro 
thrombogenicity test. 
7.5 Conclusions 
In conclusion, these studies demonstrated reduced thrombus formation on zirconium pivots 
compared to ceramic. Washout holes did not further improve thrombus formation, nor did the holes 
increase platelet activation. This in vitro test, however may not be sensitive enough to illuminate 
the effects of the washout holes. In terms of practical design, based on these studies, there is no 
drawback to incorporating the washout holes and zirconium pivots into the ModELAS. This work 
represents the initial steps in creating an in vitro thrombogenicity protocol for evaluation of 
ModELAS design changes, but further refinement of the in vitro protocol is needed to increase the 
sensitivity of this test. 
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8.0 Summary and Conclusion 
Mechanical ventilation has typically been the primary treatment for patients with acute or 
chronic respiratory failure. Less invasive, lung protective mechanical ventilation techniques have 
improved the treatment of patients. The lower tidal volumes, however can be ineffective at 
removing CO2 and necessitate returning to invasive mechanical ventilation. In patients with 
hypercapnic respiratory failure, the additional CO2 removal provided by extracorporeal CO2 
removal (ECCO2R) devices has been shown to allow extubation, prevent intubation, or permit 
lung-protective ventilation. For patients with end-stage lung disease awaiting a lung transplant, 
ECMO can provide full respiratory support and an alternative to mechanical ventilation. These 
systems, however, are still complex and often limit patient mobility or require sedation. 
Commercial devices designed specifically for the needs of children are even more limited due to 
the small patient population. The Modular Extracorporeal Lung Assist System (ModELAS) 
developed in this dissertation addresses the need for a compact, wearable artificial lung device 
while, through the platform nature of this technology, also leverages the adult ECCO2R market in 
an effort to bring the pediatric device to market. The objective of this dissertation was to develop 
the low-flow ECCO2R and pediatric full respiratory support applications of the ModELAS. 
The ModELAS is a highly compact, wearable platform technology capable of providing 
full respiratory support for children and adults as well as low-flow ECCO2R. A mathematical 
model was developed to define the bundle geometry required to meet the targeted 35 – 50% CO2 
removal rate. In vitro testing validated the model prediction and demonstrated the low-flow 
ECCO2R ModELAS is capable of removing 92 mL CO2/min, under normocapnic conditions, at a 
blood flow rate of 500 mL/min with minimal hemolysis (in vitro TIH: 0.08 g/100min & NIH: 
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0.158 g/100L). Given this data, the ECCO2R device was evaluated in 7-day in vivo studies. These 
studies demonstrated consistent gas transfer performance with only isolated device related events. 
Anemia occurred during several in vivo trials and led to an in vitro investigation of the relationship 
between hematocrit and CO2 removal. These studies demonstrated a linear decrease in vCO2 as 
hematocrit decreases and a need to take hematocrit into account when interpreting changes in CO2 
removal. 
The pediatric ModELAS was evaluated in acute and chronic animal studies. The acute 
studies evaluated the in vivo performance of the device and developed the cannulation strategy. 
The results demonstrated successful acute performance which supported in vitro data. Chronic, 7-
day studies utilized the cannulation strategies developed during the acute studies. The primary goal 
of the 7-day studies was to find a post-surgical anticoagulation and recovery strategy which 
balanced the device’s need for anticoagulation and the need for coagulation at the surgical site. 
Although only 3 studies were completed, the final animal recovered well and this post-surgical 
strategy will be implemented during upcoming 30-day studies. Additional repetitions were not 
completed due to experience with the adult ModELAS 30-day studies which demonstrated 
thrombus formation within the pump.  
Animal studies, however, are an expensive and time intensive means of determining if and 
where thrombus forms within a device. An in vitro thrombogenicity test was developed to evaluate 
the effect of impeller design modifications on thrombus formation. Results showed that the 
zirconium pivot significantly reduced thrombus surface area at the bottom pivot, however no 
significant effect was demonstrated by the addition of washout holes. Platelet activation caused by 
the washout holes was inconclusive due to noise generated by the circuit. 
 
105 
ModELAS evaluation and design optimization is on-going. Further improvements to the 
impeller washout hole design have been made and are currently being evaluated in 30-day in vivo 
studies with the adult full respiratory support ModELAS. The improved impeller design will be 
used during future 30-day, in vivo pediatric ModELAS studies. The laboratory is also developing 
a tip-to-tip thromboresistant coating133 which may allow reductions in the required systemic 
anticoagulation. Further improvements to the thrombogenicity study protocol, including blood 
inclusion criteria, may increase the power of the in vitro thrombogenicity results.  
8.1 Future Visions 
Artificial lungs will likely follow the path of artificial hearts. As the technology progresses 
patients will move from intensive care units to step-down units and eventually be discharged home 
on destination therapy devices. For this to become a reality, the pump and HFM bundle will need 
to be compact, power and oxygen supplies portable and a controller with smart feedback all while 
accounting for human factors. The ModELAS technology is not there, yet, but provides the 
primary design for which further product development will build from. 
Thrombus formation within the ModELAS pump must be addressed in order for long-term 
(1 – 3 months) artificial lung support with this device to be realized. Again, research from 
ventricular assist technology can be translated to artificial lungs. The impeller washout holes 
currently incorporated into the ModELAS were based upon designs used in ventricular assist 
devices and have improved the pump performance. Completion of 30-day in vivo studies will 
demonstrate if these design modifications have solved the thrombus formation issue or if additional 
changes are required. Ultimately, transitioning from a pivot-bearing impeller to a magnetically 
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levitated impeller may be required for long-term support. Intrabundle thrombus has not been a 
consistent issue during ModELAS animal studies completed at present, however the HFM bundle 
does represent a significant non-biologic surface and HFM bundle biocompatibility may be a 
challenge after several months of support. The application of a biocompatible surface coating 
would improve long-term device performance and in a future, outpatient setting potentially prevent 
thrombus formation due to patient compliance with anticoagulation medicines. 
The CO2 removal mathematical model presented within this dissertation can be further 
built-upon in order to improve the accuracy of the gas transfer prediction across the full range of 
ModELAS blood flow rates. The current model treats the oxygenation and CO2 removal occurring 
within the bundle as separate entities. The oxygen saturation however affects the CO2 content of 
blood and the CO2 diffusivity, and changes along the length of the HFM bundle. This relation, the 
Haldane Effect, can be taken into account by coupling CO2 and O2 transfer models. This 
dissertation has also demonstrated the need to include the hematocrit as an input parameter. These 
two modifications would likely further improve the predictive capabilities of the model, especially 
at higher blood flow rates.  
Clinical interest in ECCO2R has grown due to positive clinical data and will likely continue 
to grow with positive outcomes from on-going pivotal clinical trials. This will likely further 
increase industry interest and drive innovative ECCO2R device designs focused on additional 
reductions in invasiveness, circuit complexity and advancing ideas explored in academia. Low 
HCT environments may present the prime application of carbonic anhydrase immobilized fibers 
due to less competition with native carbonic anhydrase. Specifically in systems, such as the 
ProLung167 (Estor S.P.A., Milano, Italy; formerly the Hemodec DECAPsmart), which recirculate 
plasma through the HFM bundle. Work from this dissertation suggests that, since the hematocrit 
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is only locally decreased through the oxygenator, the CO2 carrying capacity of the blood would 
not be altered. This, in combination with reduced native carbonic anhydrase competition, may 
result in enhancements that make developing stable, carbonic anhydrase coatings worthwhile. 
Industry interest in commercializing a pediatric device will also be a challenge due to the 
small patient population. This has been the case for innovation in, and market variety of, pediatric 
ventricular assist devices. The solution may be to couple the pediatric application to a second larger 
market. For this approach to truly work, however devices will need to be designed with this goal 
in mind so that the device is optimized for each application. The Xenios AG’s iLA Activve product 
line provides a range of similarly designed oxygenators for partial CO2 removal, and pediatric and 
adult ECMO. The ModELAS design takes a similar approach, but has optimized fiber bundle 
geometries for each application and has created a compact pump-lung system. The in vivo work 
in this dissertation will be continued to evaluate the in vivo performance of the pediatric 
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